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                                              1. INTRODUCTION 
     1.1 ORAL SOLID DOSAGE FORMS:       ( Lachman, L., et al., 1990) 
A solid dosage form is drug delivery system that includes tablets, capsules, 
sachets and pills as well as a bulk or unit-dose powders and granules. Among the 
various dosage forms oral solid dosage forms have greater importance and occupy a 
prime role in the pharmaceutical market. Oral route of drug administration is widely 
acceptable and drugs administered orally as solid dosage form represents the preferred 
class of products. Over 90% of drugs formulated to produce systemic effects are 
produced as solid dosage forms. Because of these reason whenever New chemical 
entity (NCE) has discovered, which shows a sufficient pharmacological action, first 
the pharmaceutical company asks whether the drug is successfully administered by 
oral route or not. The oral route of administration still continues to be the most 
preferred route due to its manifold advantages including: 
Tablets and capsules represent unit dosage forms in which the accurate dose of drug 
to show sufficient pharmacological action can be administered. In case of liquid oral 
dosage forms such as Syrups, Suspensions, Emulsions, Solutions and Elixirs the 
patient is asked to administer the medication of   5-30 ml. Such dosage measurements 
are typically error by factor ranging from 20-50 %, when the drug is self administered 
by patient. 
Solid dosage forms are less expensive to shipping and less prone for the degradation 
when compared to liquid dosage forms.  
1.1.1 Tablets: 
“In 1843, the first patent for a hand operated device used to form a tablet was 
granted.” Tablets are defined as solid preparations each containing a single dose of 
one or more active ingredients and obtained by compressing uniform volumes of 
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particles. They are intended for oral administration, some are swallowed whole, some 
after being chewed. Some are dissolved or dispersed in water before being 
administered and some are retained in the mouth, where the active ingredient 
“liberated”. Tablets are used mainly for systemic drug delivery but also for local drug 
action. For systemic use drug must be released from tablet that is dissolved in the 
fluids of mouth, stomach and intestine and then absorbed into systemic circulation by 
which it reaches its site of action. Tablets remain popular as a dosage form because of 
the advantages, afforded both to the manufacturer [e.g. simplicity and economy of 
preparation, stability and convenience in packing, shipping and dispensing] and the 
patient [e.g. accuracy of dosage, compactness, portability, blandness of taste and ease 
of administration]. 
They may differ greatly in size and weight depending on the amount of drug 
substance present and the intended method of administration. They may have lines or 
break-marks and may bear a symbol or other markings. Tablets may be coated. 
1.1.1.1 Advantages of tablets: 
They are a unit dosage form, and they offer the greater capabilities of all oral 
dosage forms for the greatest dose precision and the least content variability. 
 They are the lightest and most compact of all oral dosage forms. 
 Product identification is potentially the simplest and cheapest, requiring no additional 
processing steps when employing an embossed or monogrammed punch face. 
 They are in general the easiest and cheapest to package and ship of all oral dosage 
forms. 
 They may provide the greatest ease of swallowing with least tendency for “hang-up” 
above the stomach. Especially when coated, provided that tablet disintegration is not 
excessively rapid.  
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 They lend themselves to certain special release profile products, such as enteric or 
delayed release products.  
 They are better suited to large scale production than other unit oral forms. 
 They have the best-combined properties of chemical, mechanical and microbiological 
stability of all the oral forms. 
 One of the major advantages of tablet over capsules is that the tablet is essentially 
“tamper proof dosage form”. 
1.1.1.2 Disadvantages of tablets: 
 Some drugs resist compression into dense compacts, owing to their amorphous nature 
or flocculent, low-density character. 
 Drugs with poor wetting, slow dissolution properties, intermediate to large dosages, 
optimum absorption high in the gastrointestinal tract, or any combination of these 
features may be difficult or impossible to formulate and manufacture as a tablet. 
 Bitter tasting drugs, drugs with objectionable odor or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation or a special type of 
coating which may increase the weight of the finished products 
1.1.1.3 Types of tablets: 
The main reasons behind formulation of different types of tablets are to create 
a delivery system that is relatively simple and inexpensive to manufacture, provide 
the dosage form that is convenient from patient‟s perspective and utilize an approach 
that is unlikely to add complexity during regulatory approval process. To understand 
each dosage form, tablets here are classified by their route of administration and by 
the type of drug delivery system they represent within that route. 
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A. Tablets ingested orally: 
1. Compressed tablet, e.g. Paracetamol tablet 
2. Multiple compressed tablet 
3. Repeat action tablet 
4. Delayed release tablet, e.g. Enteric coated Bisacodyl tablet 
5. Sugar coated tablet, e.g. Multivitamin tablet 
6. Film coated tablet, e.g. Metronidazole tablet 
7. Chewable tablet, e.g. Antacid tablet 
B. Tablets used in oral cavity: 
1. Buccal tablet, e.g. Vitamin-c tablet 
2. Sublingual tablet, e.g. Vicks Menthol tablet 
3. Troches or lozenges 
4. Dental cone 
C. Tablets administered by other route: 
1. Implantation tablet 
2. Vaginal tablet, e.g. Clotrimazole tablet 
D. Tablets used to prepare solution: 
1. Effervescent tablet, e.g.  tablet (Aspirin) 
2. Dispensing tablet, e.g. Enzyme tablet (Digiplex) 
3. Hypodermic tablet 
4. Tablet triturates e.g. Enzyme tablet (Digiplex) 
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A. Tablets ingested orally: 
1.   Compressed tablets: 
Standard uncoated tablets are manufactured by compression. The general 
methods are by wet granulation, dry granulation or direct compression, used for rapid 
disintegration and drug release. Both type of action – systemic effect and local effect. 
2. Multiple Compressed tablets:  
For incompatible components these are formulated in two ways: 
I.  Layered tablet- These are either two layered (for two components) or three layered 
(for three components) tablets. 
II.   Compression Coated type- These are either tablet within a tablet or tablet within a 
tablet within a tablet. Tablet in this category are usually prepared for two reasons 
 To separate physically or chemically incompatible ingredients. 
 To produce repeat action or prolong action product. 
3. Repeat action tablet: 
Sugar coated or multiple compressed tablets are used for this purpose. The 
core tablet is usually coated with Shellac or an enteric polymer so that it will not 
release its drug in stomach but intestine. 
4. Delayed action and Enteric-coated tablet: 
This dosage form is intended to release the drug after some time delay or after 
the tablet has passed one part of the GIT into another. All Enteric coated tablets are 
type of Delayed action tablet but all Delayed action tablets are not Enteric or not 
intended to produce enteric action. 
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5. Sugar coated tablet: 
Primary role of Sugar coating is to produce an elegant, glossy tablets. These 
are easy to swallow and multivitamin and multivitamin mineral combination. Sugar 
coating doubled the tablet weight. Now polymers are used with sugar solution. 
6. Film Coated tablet: 
One type of coated tablet in which drug is not required in coating. Polymers 
such as Hydroxy propyl cellulose, Hydroxy propyl methyl cellulose, and colloidal 
dispersion of Ethyl cellulose are commonly used. A 30% dispersion of Ethyl 
cellulose, is known as Aqua coat, is widely used in film coating. Advantage of film 
coated over sugar widely utilized in preparing coated tablets is better mechanical 
strength and flexibility of the coating, little increase in tablet weight. 
7. Chewable tablet: 
These are intended to be chewed in the mouth before swallowing. Used for 
large tablet of antacid. Bitter or foul testing drugs are not suitable for this type tablet. 
B. Tablets used in oral cavity: 
1. Buccal and sublingual tablet: 
These tablets are small, flat and are intended to be held between the cheek and 
teeth or in cheek pouch (buccal tablet) or below the tongue (sublingual tablet). Drugs 
used by this route are for quick systematic action. The tablets are designed not to be 
disintegrated but slowly dissolve. 
2. Troches and lozenges: 
These are used in the oral cavity to exert local effect in mouth and throat. They 
are commonly used to treat sore throat or to control coughing in common cold. They 
may contain local anesthetics, antiseptic, antibacterial agents, demulcents, astringent 
and antitussive. These tablets are dissolving slowly over a period of 30 minutes. 
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3. Dental cone: 
These tablets are designed to be placed in the empty socket remaining after 
tooth extraction. Main purpose is to prevent microbial growth in the socket or to 
reduce bleeding. 
C. Tablets administered by other route: 
1. Implantation tablets: 
These tablets are designed for substances implantation to provide prolonged 
drug effect from one month to a year; tablets are usually small, cylindrical not more 
than 8mm length. These methods require special surgical technique for implantation 
and discontinuation of therapy.  
2. Vaginal tablets: 
These are designed to undergo slow dissolution and drug release in vaginal 
cavity. Tablets are wide or pear shaped, used to produce antibacterial, antiseptic and 
astringent effects to treat vaginal infection. 
D. Tablets used to prepare solution: 
1. Effervescent tablets: 
Tablets are designed to produce a solution rapidly with the release of carbon 
dioxide. The tablets are prepared by compressing the active ingredient with mixture of 
organic acid such as Citric acid or Tartaric acid and Sodium bicarbonate. 
2. Dispersing tablets: 
Tablets are intended to be added to a given volume of water to produce a 
solution of a given drug concentration. 
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3. Hypodermic tablets: 
These tablets are composed of one or more drugs with water-soluble 
ingredients. Drug is added to sterile water to prepare sterile solution, which is 
injectable. 
4. Tablet triturates:                                                                           (Ansel., 2006) 
Usually these are made from moist materials using a triturate mold, which 
gives them the shape of cylinder. Generally these tablets consisting of highly potent 
drugs  
1.1.1.4 Manufacturing defects in tablets: 
Problems involved during the manufacturing of tablets include: 
 Capping  
 Lamination 
 Chipping 
 Sticking  
 Picking 
 Mottling 
 Hardness variation 
 Double impression                                                                   (Jhong, A., 2011) 
1.2 CURRENT TECHNOLOGIES IN ORAL DRUG DELIVERY: 
                Over the last 3 decades, many novel oral drug therapeutic systems have 
been invented along with the appreciable development of drug delivery technology. 
Although these advanced drug delivery systems are manufactured or fabricated in 
traditional pharmaceutical formulations, such as Tablets, Capsules, Sachets, 
Suspensions, Emulsions, and Solutions, they are superior to the conventional oral 
dosage forms in terms of their therapeutic efficacies, toxicities, and stabilities. 
Formulation and evaluation of Sorafenib tosylate      Introduction  
 
Adhiparasakthi College of Pharmacy, Melmaruvathur  Page 9 
 
1.2.1 Based on the desired therapeutic objectives, oral DDS may be assorted into 
three categories: 
I.  Immediate-release preparations. 
II. Controlled-release preparations. 
III. Targeted- release preparations. 
I. Immediate-Release Preparations: 
                Immediate release drug delivery system is also conventional type of drug 
delivery system and it is defined as immediate release of drug without any special rate 
controlling features such as special coatings and other techniques. 
                These preparations are primarily intended to achieve faster onset of action 
for drugs such as analgesics, antipyretics, and coronary vasodilators. Other 
advantages include enhanced oral bioavailability through transmucosal delivery and 
pre-gastric absorption, convenience in drug administration to dysphasic patients, 
especially the elderly and bedridden, and new business opportunities. Conventional IR 
formulations include fast disintegrating tablets and granules that use effervescent 
mixtures, such as sodium carbonate (or sodium bicarbonate) and citric acid (or tartaric 
acid), and superdisintegrants , such as sodium starch glycolate, crosscarmellose 
sodium, and crosspovidone. Current technologies in fast-dispersing dosage forms 
include modified tabulating systems, floss or Shear form technology, which employs 
application of centrifugal force and controlled temperature, and freeze-drying. 
 II. Controlled-Release (CR) Preparations: 
                The currently employed CR technologies for oral drug delivery are 
diffusion-controlled systems; solvent activated systems, and chemically controlled 
systems. 
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                Diffusion-controlled systems include monolithic and reservoir devices in 
which diffusion of the drug is the rate-limiting step, respectively, through a polymer 
matrix or a polymeric membrane.  
                 Solvent-activated systems may be either osmotically controlled or 
controlled by polymer swelling.  
                 Chemically controlled systems release drugs via polymeric degradation 
(surface or bulk matrix erosion) or cleavage of drug from a polymer chain. It is worth 
mentioning here that the so-called programmed-release („„tailored-release‟‟) profile of 
a final CR product is rarely the outcome of a single pharmaceutical principle. 
Depending on the specific physicochemical properties of the drug in question and 
desired therapeutic objectives, different formulation and CR principles may be 
proportionally combined within the same dosage form. This task appears to be 
simpler when realized in terms of appropriate selection of polymers and excipients 
that incorporate desired principles. 
III. Targeted-Release Preparations:                                (Saltzman, W., et al., 2008) 
   Targeted drug delivery, sometimes called smart drug delivery. Targeted 
drug delivery systems have been developed to optimize regenerative techniques. The 
system is based on a method that delivers a certain amount of a therapeutic agent for a 
prolonged period of time to a targeted diseased area within the body. This helps 
maintain the required plasma and tissue drug levels in the body. Therefore, avoiding 
any damage to the healthy tissue via the drug. The drug delivery system is highly 
integrated and requires various disciplines, such as chemists, biologist and engineers, 
to join forces to optimize this system
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1.3 METHODS USED IN TABLET MANUFACTURING:   (Lieberman H.A. and 
Lachman L., 1999; Ansel H.C., 2009; http://www.pharmainfo.net) 
Granulation:       
 Granulation may be defined as a size enlargement process which converts 
small particles into physically stronger & larger agglomerates. 
The reason for granulation: 
  Become the pharmaceutical ingredient are free flowing 
  Increase the denseness of  ingredient 
  We can formulate uniform granular size that does not existing apart  
  Produce better  compression  characteristic  of  drug 
  Controlling  the  rate of  drug release from the dosage form 
  Reduce  dust in granulation technique 
  The  appearance  of  tablet can be achieved 
Methods: 
  1. Direct compression  
  2. Wet granulation 
  3. Dry granulation     
1.3.1. Direct compression: 
                In early days, most of the tablets require granulation of the powdered Active 
Pharmaceutical Ingredient (API) and Excipients. At the availability of new excipients 
or modified form of old excipients and the invention of new tablet machinery or 
modification of old tablet machinery provides an ease in manufacturing of tablets by 
simple procedure of direct compression. 
            Amongst the techniques used to prepare tablets, direct compression is the most 
advanced technology. It involves only blending and compression. Thus offering 
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advantage particularly in terms of speedy production. Because it requires fewer unit 
operations, less machinery, reduced number of personnel and considerably less 
processing time along with increased product stability. 
1.3.1.1. Definition:  
 The term “direct compression” is defined as the process by which tablets are 
compressed directly from powder mixture of API and suitable excipients. No 
pretreatment of the powder blend by wet or dry granulation procedure is required. 
1.3.1.2. The events that motivates the industry people to use direct compression 
technique:  
I. Commercial availability of the directly compressible excipients possessing both 
good compressibility and good flow ability. For example, Spray dried lactose, 
Anhydrous lactose, Starch-1500, microcrystalline cellulose, sorbitol. 
II. Major advances in tablet compression machinery: 
i)  Improved positive die feeding, 
ii) Precompression of powder blend. 
1.3.1.3 Merits: 
i) Direct compression is more efficient and economical process as compared to other 
processes, because it involves only dry blending and compaction of API and 
necessary excipients. 
ii) The most important advantage of direct compression is economical process. 
Reduced processing time, reduced labor costs,  fewer manufacturing steps, and less 
number of equipments are required, less process validation, reduced consumption of 
power.  
iii) Elimination of heat and moisture, thus increasing not only the stability but also the 
suitability of the process for thermolabile and moisture sensitive API‟s. 
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iv) Particle size uniformity. 
v) Prime particle dissolution. 
 In case of directly compressed tablets after disintegration, each primary drug 
particle is liberated. While in the case of tablets prepared by compression of granules, 
small drug particles with a larger surface area adhere together into larger 
agglomerates; thus decreasing the surface area available for dissolution. 
vi) The chances of batch-to-batch variation are negligible, because the unit operations 
required for manufacturing processes is fewer. 
vii) Chemical stability problems for API and excipient would be avoided. 
viii) Provides stability against the effect of aging which affects the dissolution rates. 
1.3.1.4. Merits over wet granulation process: 
 The variables faced in the processing of the granules can lead to significant 
tableting problems. Properties of granules formed can be affected by viscosity of 
granulating solution, the rate of addition of granulating solution, type of mixer used 
and duration of mixing, method and rate of dry and wet blending. The above variables 
can change the density and the particle size of the resulting granules and may have a 
major influence on fill weight and compaction qualities. Drying can lead to 
unblending as soluble API migrates to the surface of the drying granules. 
1.3.1.5. Demerits: 
Excipients Related:  
i) Problems in the uniform distribution of low dose drugs. 
ii) High dose drugs having high bulk volume, poor compressibility and poor flowability 
are not suitable for direct compression. 
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iii) The choice of excipients for direct compression is extremely critical. Direct 
compression diluents and binders must possess both good compressibility and good 
flow ability. 
iv)  Many active ingredients are not compressible either in crystalline or amorphous 
forms. 
v) Direct compression blends may lead to unblending because of difference in particle 
size or density of drug and excipients. Similarly the lack of moisture may give rise to 
static charges, which may lead to unblending. 
vi) Non-uniform distribution of colour, especially in tablets of deep colours. 
Process Related: 
i) Capping, lamination, splitting, or layering of tablets is sometimes related to air 
entrapment during direct compression. When air is trapped, the resulting tablets 
expand when the pressure of tablet is released, resulting in splits or layers in the 
tablet. 
ii)  In some cases require greater sophistication in blending and compression equipments. 
iii) Direct compression equipments are expensive. 
1.3.1.6 Manufacturing steps for direct compression: 
 Direct compression involves comparatively few steps: 
  Milling of drug and excipients. 
  Mixing of drug and excipients. 
  Tablet compression. 
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Figure 1.1: Manufacturing Steps for Direct Compression. 
1.3.1.7. Direct compression Excipients: 
 Direct compression excipients mainly include diluents, binders and 
disintegrants. Generally these are common materials that have been modified during 
the chemical manufacturing process, in such a way to improve compressibility and 
flowability of the material. 
 The physicochemical properties of the ingredients such as particle size, 
flowability and moisture are critical in direct compression tableting. The success of 
direct compression formulation is highly dependent on functional behavior of 
excipients. 
1.3.1.7.1. An ideal direct compression excipient should possess the following 
attributes:  
 i)  It should have good compressibility. 
ii) It should possess good hardness after compression, that is material should not 
possess any deformational properties; otherwise this may lead to capping and 
lamination of tablets. 
iii) It should have good flow ability. 
iv) It should be physiologically inert. 
v) It should be compatible with wide range of API. 
vi) It should be stable to various environmental conditions (air, moisture, heat, etc.). 
vii) It should not show any physical or chemical change in its properties on aging. 
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viii) It should have high dilution potential i.e. able to incorporate high amount of API.     
ix) It should be colourless, odorless and tasteless. 
 x) It should accept colourants uniformity. 
 xi) It should possess suitable organoleptic properties according to formulation type, 
that is in case of chewable tablet diluent should have suitable taste and flavor. For 
example, mannitol produces cooling sensation in mouth and also sweet test. 
 xii) It should not interfere with bioavailability and biological activity of active 
ingredients. 
xiii) It should be easily available and economical in cost. 
Granulation method can be broadly classified into two types:  
 Wet granulation and  
 Dry granulation. 
1.3.2. Wet granulation: 
The most widely used process of agglomeration in pharmaceutical industry is 
wet granulation. Wet granulation process simply involves wet massing of the powder 
blend with a granulating liquid, wet sizing and drying. 
1.3.2.1. Important steps involved in the wet granulation: 
i)   Mixing of the drugs and excipients 
ii)  Preparation of binder solution 
iii) Mixing of binder solution with powder mixture to form wet mass. 
iv) Coarse screening of wet mass using a suitable sieve (6-12 # screens). 
v)  Drying of moist granules. 
vi) Screening of dry granules through a suitable sieve (14-20 # screen). 
vii)  Mixing of screened granules with disintegrant, glidant, and lubricant. 
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1.3.2.2. Limitations of wet granulation: 
i)  The greatest disadvantage of wet granulation is its cost. It is an expensive process 
because of labor, time, equipment, energy and space requirements. 
ii) Loss of material during various stages of processing  
iii) Stability may be major concern for moisture sensitive or thermo labile drugs  
iv) Multiple processing steps add complexity and make validation and control 
difficult. 
v) An inherent limitation of wet granulation is that any incompatibility between 
formulation components is aggravated. 
1.3.3. Dry granulation: 
In dry granulation process the powder mixture is compressed without the use 
of heat and solvent. It is the least desirable of all methods of granulation. The two 
basic procedures are to form a compact of material by compression and then to mill 
the compact to obtain a granules. Two methods are used for dry granulation. The 
more widely used method is slugging, where the powder is pre-compressed and the 
resulting tablet or slug are milled to yield the granules.  
The other method is to pre-compress the powder with pressure rolls using a 
machine such as Chilosonator. 
1.3.3.1. Advantages: 
The main advantages of dry granulation or slugging are that it uses less 
equipments and space. It eliminates the need for binder solution, heavy mixing 
equipment and the costly and time consuming drying step required for wet 
granulation. Slugging can be used for advantages in the following situations: 
i) For moisture sensitive material 
ii) For heat sensitive material 
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iii) For improved disintegration since powder particles are not bonded together by a 
binder 
1.3.3.2. Disadvantages: 
i) It requires a specialized heavy duty tablet press to form slug 
ii) It does not permit uniform colour distribution   
iii) Achieved with wet granulation where the dye can be incorporated into binder 
liquid. 
iv) The process tends to create more dust than wet granulation, increasing the 
potential contamination. 
1.4. INTRODUCTION TO TABLET COATING: 
                  Coated tablets are covered with one/more layers of mixtures of various 
substances such as natural waxes authorized colouring materials. Substances used for 
coating are usually applied as solution/suspension under condition where vehicle 
evaporates. In the past sugar coating was mostly borrowed from the confectionary 
industry. But in now a days it is replaced with film coating. 
                   Tablet film coating is performed by two types, one is aqueous film coating 
(generally water is used as a solvent) and non aqueous film coating (generally organic 
solvent are used). Some problems are associated with the non aqueous film coating 
like employee safety (it‟s dangerous, it smells, and it‟s not good to breathe) 
atmosphere pollution etc. But key problem is with the approval of the regulatory 
authority. High quality aqueous film coating must be smooth, uniform and adhere 
satisfactorily to the tablet surface and ensure chemical stability of a drug. 
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 1.4.1. Reasons for Tablet Coating:                                     (Cole, G., et al., 1998) 
 The core contains a material which has a bitter taste in the mouth or has an unpleasant 
odour. 
 Coating will protect the drug from the surroundings with a view to improve its 
stability. 
 The core contains a substance which is incompatible in the presence of light and 
subject to atmospheric oxidation, i.e. a coating is added to improve stability. 
 The active substance is coloured and migrates easily to stain hands and clothes. 
 The coated tablets can be packed on high-speed packaging machine. Coating reduces 
friction and increases packaging rate. 
 Coating can modify the drug release profile, e.g., enteric coating, osmotic pump, 
pulsatile delivery2. 
 1.4.2. Film Coating Materials: 
A film coating is a thin polymer-based coat applied to a solid dosage form such as a 
tablet. The thickness of such a coating is usually between 20-100 µm. 
Film coating formulations usually contain the following components: 
1. Polymer 
2. Plasticizer 
3. Colourants / Opacifiers 
4. Solvent / Vehicle. 
1. Polymer 
Among the vast majority of the polymers used in film coating are cellulose 
derivatives or acrylic polymers and copolymers. 
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i. Non-enteric polymers: 
Hypromellose, Hydroxy ethyl cellulose, Hydroxy ethyl methyl cellulose, 
Carboxy methyl cellulose sodium, Hydroxy propyl cellulose, Polyethylene glycol, 
Ethylcellulose 
ii. Enteric polymers: 
Hypromellose phthalate, Polyvinyl acetate phthalate, Cellulose acetate 
phthalate, Polymethacrylates, Shellac 
2. Plasticizers 
The capacity to alter the physical properties of the polymer to render it more 
useful in performing its  function as a film coating material. It is generally considered 
to be mechanism of plasticizer molecule to interpose themselves between individual 
polymer strands thus breaking down polymer-polymer interactions. Thus polymer is 
converted in to more pliable materials. Plasticizers are classified in three groups. 
Polyos type contains glycerol, propylene glycol, PEG (Polyethyleneglycol). Organic 
esters contain phthalate esters, dibutyl sebacetate, citrate esters, triacetin. 
Oils/glycerides contain castor oil, acetylated, monoglycerides, and fractionated 
coconut oil. 
3. Solvents/Vehicles 
                  The key function of a solvent system is to dissolve or disperse the 
polymers and other additives. All major manufactures of polymers for coating give 
basic physicochemical data on their polymers. These data are usually helpful to a 
formulator. 
The major classes of solvents being used are 
•Water 
•Alcohols 
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•Ketones 
•Esters 
•Chlorinated hydrocarbons 
Because of environmental and economic considerations, water is the solvent of 
choice; however organic coating is totally cannot be avoided.  
4. Colourants / Opacquants: 
These materials are generally used as ingredients in film-coating formulae to 
contribute to the visual appeal of the product, but they also improve the product in 
other ways: 
• Identification of the product by the manufacturer and therefore act as an aid for 
existing GMP procedures. 
• Reinforcement of brand imaging and reduction in product counterfeiting. 
• Identification of the product by patients by using colourants. 
                 Colourants for film coating are having, more or less amount and property 
of pacifier. So they would give protection to active ingredients in presence of light. 
Colourants are mainly classified in to three parts. Sunset yellow, Tartrazine, 
Erythrosine are examples of Organic dyes and their lakes. Iron oxide yellow, red and 
black, Titanium dioxide,  Talc are the examples of Inorganic colours. Anthrocyanins, 
Ribofloavine and Carmine are the examples of natural colours. 
1.4.3. Miscellaneous coating solution components: 
Flavours and sweeteners are added to mask unpleasant odours or to develop the 
desired taste. 
 For example Aspartame, various fruit spirits (organic solvent), water soluble 
pineapple flavor (aqueous solvent) etc. 
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Surfactants are supplementary to solubilize immiscible or insoluble ingredients in the 
coating.  
For example : Spans, Tweens etc. 
Antioxidants are incorporated to stabilize a dye system from oxidation and colour 
change.  
For example : Oximes, Phenols etc. 
Antimicrobials are added to put off microbial growth in the coating composition. 
Some aqueous cellulosic coating solutions are mainly prone to microbial growth, and 
long-lasting storage of the coating composition should be avoided. 
 For example : Alkyl iso thiazloinone, Carbamates, Benzothiazoles etc 
(Hogan, J., 1998) 
1.4.4. Coating Process: 
                  Film-coating of tablets is a multivariate process, with many different 
factors, such as coating equipment, coating liquid, and process parameters which 
affect the pharmaceutical quality of the final product. 
1.4.4.1. Coating equipment:                                            (Heinamaki, J., et al., 1997) 
Before few years different types of coating pans are used for coating like 
conventional coating pans, manesty accelacota, Driam (Driacoater), butterfly coater 
etc. Now a days the side-vented, perforated pan-coater is the most commonly used 
coating device of tablets. In equipment spray nozzle, number of spray nozzle, pan 
size, etc may also affect the quality of final product. Its air flow system through a 
perforated pan ensures rapid and continuous drying conditions. 
1.4.4.2. Coating liquid: 
                  Coating liquid may affect the final quality of the tablets. Different film 
former have different chemical nature and different characteristics. Viscosity may 
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affect the spreading of coating liquid across surface of substrate. Surface tension may 
affect in wetting of surface. % Solid content generally affects the tablet surface and 
coating efficiency. 
1.4.5. Process parameters: 
1.4.5.1. Spray rate                                                                   (Obara, S., et al., 1995) 
 The spray rate is an significant parameter since it impacts the moisture 
content of the formed coating and, subsequently, the quality and uniformity of the 
film. A low coating liquid spray rate causes incomplete coalescence of polymer due to 
insufficient wetting, which could effect in brittle films. A high coating liquid spray 
rate may result in over wetting of the tablet surface and subsequent problems such as 
picking and sticking. If the spray rate is high and the tablet surface temperature is low, 
films are not formed during the spraying but the post drying phase and rapid drying 
often produces cracks in the films.  
1.4.5.2 Atomizing air pressure                                             (Tobiska, S., et al., 2003) 
   In general, increasing the spraying air pressure decreases the surface 
roughness of coated tablets and produces denser and thinner films. If spraying air 
pressure is excessive, the spray loss is great, the formed droplets are very fine and 
could spray-dry before reaching the tablet bed, resulting in inadequate droplet 
spreading and coalescence. If spraying air pressure is inadequate, the film thickness 
and thickness variation are greater possibly due to change in the film density and 
smaller spray loss. In addition, with low spraying air pressure big droplets could 
locally over wet the tablet surface and cause tablets to stick to each other 
1.4.5.3. Inlet air temperature.                                              (Okutgen, E., et al., 1991) 
 The inlet air temperature affects the drying efficiency (i.e. water 
evaporation) of the coating pan and the uniformity of coatings. High inlet air 
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temperature increases the drying efficiency of the aqueous film coating process and a 
decrease in the water penetration into the tablet core decreases the core tablet 
porosity, tensile strength and residual moisture content of coated tablets. Too much air 
temperature increases the premature drying of the spray during application and, 
subsequently, decreases the coating efficiency. Measuring the pan air temperature 
helps to manage the optimum conditions during the coating process and, 
consequently, enables predicting possible drying or over wetting problems which may 
result in poor appearance of the film or may have unfavorable effects on the moisture 
and heat sensitive tablet cores 
1.4.5.4. Rotating speed of pan                                             (Wilson, K., et al., 1997)   
 It is well documented that increasing the rotating speed of the pan 
improves the mixing of tablets. The pan speed affects the time the tablets spend on the 
spraying zone and, subsequently, the homogeneous distribution of the coating solution 
on the surface of each tablet throughout the batch. Increasing the pan speed decreases 
the thickness variation and increase the uniformity of coatings. Too much rotating 
speed of the pan will cause the tablet to undergo unnecessary attrition and breakage  
1.5. INTRODUCTION TO CANCER: 
Cancer is a class of diseases characterized by out-of-control cell growth. There 
are over 100 different types of cancer, and each is classified by the type of cell that is 
initially affected. 
1.5.1. Renal Cell Carcinoma:                                                ( Rini, B.I., et al., 2008) 
 Renal cell carcinoma (RCC, also known as Hyper nephroma) is a kidney 
cancer that originates in the lining of the proximal convoluted tubule, the very small 
tubes in the kidney that filter the blood and remove waste products. RCC is the most 
common type of kidney cancer in adults, responsible for approximately 80% of cases. 
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It is also known to be the most lethal of all the genitourinary tumors. The metastatic 
stage of renal cell carcinoma occurs when the disease invades and spreads to other 
organs. It is most likely to spread to neighboring lymph nodes, the lungs, the liver, the 
bones, or the brain. Metastatic renal cell carcinoma presents a special challenge to 
oncologists, as about 70% of patients develop metastases during the course of their 
disease                                          
           
                                 Figure: 1.2. Renal cell carcicoma 
1.5.2. Diagnosis: 
                  Physicians use information from symptoms and several other procedures 
to diagnose cancer. Imaging techniques such as X-rays, CT scans, MRI scans, PET 
scans, and ultrasound scans are used regularly in order to detect where a tumor is 
located and what organs may be affected by it. Doctors may also conduct an 
endoscopy, which is a procedure that uses a thin tube with a camera and light at one 
end, to look for abnormalities inside the body. 
Extracting cancer cells and looking at them under a microscope is the only 
absolute way to diagnose cancer. This procedure is called a biopsy. Physicians will 
analyze body's sugars, fats, proteins, and DNA at the molecular level. For example, 
cancerous prostate cells release a higher level of a chemical called PSA (prostate-
specific antigen) into the bloodstream that can be detected by a blood test.  
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1.5.3. Epidemiology:                                               (McLaughlin, J.K., et al., 2000)       
From 1975 to 2006, the incidence of kidney cancer rose 2% annually in the United 
States. The American Cancer Society estimated that in 2009 there would be 57,760 
cases (35,430 in males and 22,330 in females) of malignant tumors of the kidney 
diagnosed, with 12,890 deaths (8,160 in males and 4,820 in females); renal cell cancer 
(RCC) accounted for 80% of this incidence and mortality. Renal cell carcinoma is 
more common in people of Northern European ancestry (Scandinavians) and North 
Americans than in those of Asian or African descent. In addition, the incidence in 
men is greater than in women (1.6:1).  
1.5.4. Etiology: 
Cigarette smoking, Obesity, Hypertension, Phenacetin-containing analgesia 
taken in large amounts. 
1.5.5. Risk factors include: 
                  Dialysis treatment, Family history of the disease, High blood pressure, 
Horseshoe kidney, Smoking, Von Hippel-Lindau disease (a hereditary disease that 
affects the capillaries of the brain, eyes, and other body parts) 
1.5.6. Symptoms: 
Abdominal pain, Back pain, Blood in the urine, Enlargement of the veins 
around a testicle (varicocele), Swelling or enlargement of the abdomen, Unintentional 
weight loss. 
1.5.7. Signs and tests 
                 Examination of the abdomen may show a mass or organ enlargement, 
particularly of the kidney or liver. Men may have a varicocele in the scrotum (a 
varicocele that is only on the right side is especially suspicious). 
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Tests include: 
• Abdominal CT scan 
• Blood chemistry 
• Complete blood count (CBC) 
• Intravenous pyelogram (IVP) 
• Liver function tests 
• Renal arteriography 
• Ultrasound of the abdomen and kidney 
• Urinalysis and urine cytology. 
1.5.8. Treatment                                                                    (Novick, A.C., 1998)   
Surgical removal of all or part of the kidney (nephrectomy) is recommended. This 
may include removing the bladder or surrounding tissues or lymph nodes. Radiation 
therapy usually does not work for renal cell carcinoma so it is not often used. 
Hormone treatments may reduce the growth of the tumor in some cases. 
Chemotherapy is generally not effective for treating renal cell carcinoma. The drug 
interleukin-2 (IL-2), which works by helping the body‟s own immune system kill the 
cancer cells, may help a small number of patients, but it is very toxic. Other 
chemotherapy drugs have been used, but patients generally do not live long once the 
disease has spread outside the kidney Newer therapies include sorafenib (Nexavar), 
sunitinib (Sutent), and temsirolimus (Torisel). The biologic drug bevacizumab 
(Avastin) has also been used. A cure is unlikely unless all of the cancer is removed 
with surgery. 
1.5.9. Hepatocellular Carcinoma:                                   (Kumar, V., et al., 2003) 
Hepatocellular carcinoma (HCC, also called malignant hepatoma) is the most 
common type of liver cancer. Most cases of HCC are secondary to either a 
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viral hepatitide infection (hepatitis B or C) or cirrhosis (alcoholism being the most 
common cause of hepatic cirrhosis). Compared to other cancers, HCC is quite a rare 
tumor in the United States. Treatment options of HCC and prognosis are dependent on 
many factors but especially on tumor size and staging. Tumor grade is also important. 
High-grade tumors will have a poor prognosis, while low-grade tumors may go 
unnoticed for many years, as is the case in many other organs, such as the breast . 
 
                 Figure:1.3.Hepato cellular carcicoma 
1.5.9.1. Diagnosis: 
                  Hepatocellular carcinoma (HCC) most commonly appears in a patient with 
chronic viral hepatitis (hepatitis B or hepatitis C, 20%) or/and with cirrhosis (about 
80%). These patients commonly undergo surveillance with ultrasound due to the cost-
effectiveness. CT scans use contrast agents, which are typically iodine or barium 
based.Mostly the radiologists are using MRIs to do a secondary study to look at an 
area where a tumor has already been detected. 
1.5.9.2. Epidemiology: 
                  HCC is one of the most common tumors worldwide. The epidemiology of 
HCC exhibits two main patterns, one in North America and Western Europe and 
another in non-Western countries, such as those in sub-Saharan 
Africa, central and Southeast Asia, and the Amazon basin. Males are affected more 
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than females usually and it is most common between the age of 30 to 
50. Hepatocellular carcinoma causes 662,000 deaths worldwide per year about half of 
them in China. 
1.5.9.3. Signs/Symptoms 
Abdominal swelling, Vague pain upper right abdomen and back, Fatigue, 
Fever, Weight loss, Jaundice ,  Loss of appetite.
 
1.5.9.4. Risk Factors 
 Occupational exposure to chemicals, e.g. vinyl chloride, Cirrhosis, Alcohol 
abuse combined with heavy tobacco use, Hepatitis B or C, Poor nutrition. 
1.5.9.5. Treatment:                                                               (Kelley, R.K., et al., 2008)                   
 
              Figure:1.4.Treatment of Hepatocellular carcicoma by sorafenib                                           
   Treatment of liver cancer depends on the type of tumor and the stage of the disease, 
the condition of the liver, and the patient‟s age and overall health. The three main 
treatment methods include surgery, chemotherapy, and radiation therapy. Surgery to 
remove a tumor, called surgical resection, is the only way to cure liver cancer. 
Unfortunately, in the majority of liver cancers, complete removal of the cancer is not 
possible, either because the cancer has already spread beyond the liver or because the 
tumor is too large, or several tumors are present in different parts of the liver. 
Chemotherapy, the use of cancer-killing drugs, is also used to treat liver cancer. 
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Chemotherapy can be administered systemically by injection into a vein (IV) or by 
mouth. In systemic chemotherapy, the anticancer drugs enter the bloodstream and 
travel throughout the whole body, attacking cancer cells found beyond the liver.  
The targeted therapy Nexavar (Sorafenib) is the first systemic therapy to improve 
survival in hepatocellular carcinoma, and is now a standard approach to treatment 
among patients with advanced hepatocellular carcinoma  
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2.  AIM & OBJECTIVE 
  2.1. Aim of the study: 
The aim of present work is to develop a solid oral dosage form of Sorafenib 
tosylate and it‟s comparision with innovator drug (Nexavar). The formulation of 
tablets were done to match the in-vitro drug release with respect to the reference drug 
and carry out the stability studies as per the ICH guidelines. 
2.2. Objectives: 
2.2.1. Primary Objective: 
1.  To formulate and evaluate immediate release Sorafenib tosylate  film coated 
tablets 200mg. 
2.2.2. Secondary Objectives: 
1. To perform preformulation studies including drug – excipient compatibility study. 
2. To develop various formulations with different excipients. 
3. To study the effect of excipient concentrations on the tablet characteristics. 
4. To establish the invitro release compliance with the established criteria. 
5. To achieve immediate release profile for the developed formulation. 
6. To establish the stability of the formulation. 
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3. PLAN OF WORK 
The present research work was planned as per the following experimental 
protocol 
 Literature survey: 
      Literature survey on the various works carried out on this topic is reviewed. 
 Procurement of chemicals: 
      Procurement of drug and other ingredients required for the study. 
 Preformulation: 
a. Physical observation 
b. Bulk density 
c. Tapped density 
d. Hausner„s Ratio 
e. Car„s index 
f. Compatibility studies of drug with various excipients. 
 Formulation: 
           Tablets will be prepared by compression method using various grades of   excipients 
in different ratios. 
 Film coating tablets: 
Film coating will be done to prepare tablets by using film coating polymer like  
HPMC,   Advantia prime  pink 
 Evaluation of tablets: 
a. Tablet appearance 
b. Thickness 
c. Hardness 
d. Disintegration test 
e. % Friability 
f. Invitro dissolution testing 
g. Stability Studies
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4. LITERATURE REVIEW 
Anton, S., et al. (2011) This research work was aimed to formulate film 
coated tablets of secnidazole by wet granulation method and granules are compressed 
for tablets and they are coated with polymers by using Hydroxypropyl methyl 
cellulose and advatia prime pink. The resulted tablets were evaluated for different 
parameter and concluded that the coating has not shown any effect on the dissolution 
of the drug. 
Kane, R.C. (2010) This report describes the U.S. Food and Drug 
Administration (FDA) review and approval of Sorafenib (Nexavar, BAY43-9006), a 
new small-molecule, oral, multi-kinaseinhibitor for the treatment of patients with 
advanced renal cell carcinoma (RCC). Sorafenib received FDA regular approval on 
December 20, 2005 for the treatment of advanced RCC. The recommended dose is 
400 mg (two 200-mg tablets) twice daily taken either 1 h before or 2 h after meals. 
Adverse events were accommodated by temporary dose interruptions or reductions. 
Li.Y.,  et al.  (2010) report the more evidence sources to the standard 
treatment for patients with advanced hepatocellular carcinoma, the writer analyze 
patients' time to progression (TTP) and overall survival (OS) after patients receiving 
Transcatheter Arterial Chemo Embolization (TACE) combined with Sorafenib as a 
treatment of advanced hepatocellular carcinoma (HCC); observe the healing effect 
embolization combined with anti-angiogenic treatment for advanced hepatocellular 
carcinoma; and also analyze treatment of security. Combined with sorafenib treatment 
may give patients with advanced hepatocellular carcinoma a longer longevity and 
keep the disease in a steady state. This therapy can be added into the treatments to 
patients with advanced hepatocellular carcinoma. 
Formulation and evaluation of Sorafenib tosylate     Literature review 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 34 
 
Benjamin, H., et al. (2010) reported that there are multiple reports  on  
Sorafenib-induced hand  foot  skin  reaction, this  case report details a patient  
presenting with an unusually severe and  painful  skin  reaction. As the 
armamentarium of anti- neoplastic kinase inhibitors continues to increase, clinicians 
must be aware of the array of skin reactions these drugs can induce. A 66 years old 
Caucasian male with metastatic renal cell carcinoma presented with flu-like 
symptoms, rash, and painful bullous lesions of his fingertips. After empiric coverage 
with antibiotics and an infectious workup that turned up negative, it was determined 
that the patient‟s presentation was due to a severe and painful hand skin reaction to 
sorafenib. While most patients taking sorafenib will experience a cutaneous side 
effect, the hand foot skin reaction can be extremely debilitating and occurs frequently. 
Oncologists and dermatologists must be informed about the array of adverse effects o 
f kinase inhibitors. In the case report, the bullous skin reaction, debilitating hand pain, 
and absence of foot involvement were the interesting features. 
Mila, P., et al. (2010) reported that medullary thyroid cancer (MTC) is a rare 
and only surgically treatable disease with early development of metastases and bad 
prognosis. Due to the lack of efficient systemic treatment, new strategies and 
approaches are needed to better the patients‟ outcome. One of the most promising 
treatment options is the use of tyrosine multikinase inhibitors, which appear to have 
some effect on the disease progression with tolerable toxicity. They reported a case of 
a young patient with metastatic MTC treated successfully for two months with 
sorafenib. 
Tejash, S., et al. (2010) Orodispersible tablets  of  pheniramine maleate  were  
prepared by direct compression  method  using  various  superdisintegrants  like  
Crospovidone, croscarmellose sodium,  sodium starch glycolate, low substituted  
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hydroxypropyl cellulose,  pregelatinized starch. The  prepared  tablets  were  
evaluated  for  uniformity of weight, hardness, friability, wetting time, in-vitro  
disintegration time, in-vitro dispersion  time  and  drug  release study. All the 
formulation exhibited hardness between 3.3 – 3.6 kg/cm2. The tablets were 
disintegrating in–vitro within 20 to 51 sec. Dissolution studies revealed that 
formulations containing 10% Crospovidone and formulation containing                 
10% croscarmellose sodium showed 100% of drug release, at the end of six min. 
Thomas, S., et al. (2010) Sorafenib, an oral multitargeted tyrosine kinase 
inhibitor, is licensed for the treatment of hepatocellular carcinoma. Rash is one of the 
most common side effects of its use, generally appearing within days to a few weeks 
of commencing treatment. They reported the first case of rash appearing nine months 
after starting treatment with sorafenib. Sorafenib is a drug of choice in Barcelona 
Clinic Liver Cancer stage B hepatocellular carcinoma. It can cause protracted rash 
quite late into treatment. Successful management of the rash could contribute to 
achieving stable disease in hepatocellular carcinoma over a significant period of time. 
Thomas, E., et al. (2010) The phase III Treatment Approaches in Renal 
cancer Global Evaluation Trial (TARGET) indicated that sorafenib is effective and 
well tolerated in advanced renal cell carcinoma patients. However, few data have been 
published on the safety of long-term sorafenib treatment. A retrospective subgroup 
analysis was performed to evaluate the efficacy and safety of sorafenib in patients in 
TARGET who received treatment for >1 year. Results of this subgroup analysis of 
patients enrolled in TARGET who received treatment for >1 year indicate that long-
term treatment with sorafenib is associated with continued efficacy and a well-
tolerated safety profile. 
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Dok, H. Y., et al. (2010) Sorafenib is the only drug that has shown a survival 
benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials. The 
efficacy and safety of sorafenib in the treatment of recurrent hepatocellular carcinoma 
after liver transplantation, however, has not been determined. These findings suggest 
that sorafenib may be a feasible treatment option regarding its efficacy and safety for 
recurrent hepatocellular carcinoma after liver transplantation. 
Jeng, F.C., et al. (2009) Sorafenib is a newly established cancer drug found to 
be an effective systemic treatment for advanced hepatocellular carcinoma (HCC). 
However, little is known about any potential effectors that modify tumor cell 
sensitivity towards sorafenib. The first evidence that glucose-regulated protein 78 
(GRP78) is intimately associated with acquisition of resistance towards sorafenib. 
RNA interference in cancer cells was applied to determine the influence of GRP78 
expression on sensitivity to sorafenib treatment.GRP78 is a positive modifier for 
sorafenib resistance acquisition in HCC and represents a prime target for overcoming 
sorafenib resistance. 
Lettieri, J.T., et al. (2009) reported that Sorafenib is a multikinase inhibitor 
currently approved by the FDA for the treatment of advanced renal-cell carcinoma 
(RCC) and unresectable hepatocellular carcinoma (HCC). Sorafenib is available as a 
tablet formulation. Some patients who are unable to swallow tablets have suspended 
sorafenib tablets in a liquid for ease of administration. He performed a study to assess 
whether this process alters the bioavailability of sorafenib. The pharmacokinetics of 
sorafenib, when administered as a liquid suspension of tablets in water, were similar 
to the pharmacokinetics of tablets swallowed whole. 
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Ann, L.C., et al. (2009) cases of hepatocellular carcinoma occur in the Asia-
Pacific region, where chronic hepatitis B infection is an important aetiological factor. 
Assessing the efficacy and safety of new therapeutic options in an Asia-Pacific 
population is thus important. A multinational phase III, randomised, double-blind, 
placebo-controlled trial to assess the efficacy and safety of sorafenib in patients from 
the Asia-Pacific region with advanced (unresectable or metastatic) hepatocellular 
carcinoma. Sorafenib is effective for the treatment of advanced hepatocellular 
carcinoma in patients from the Asia-Pacific region, and is well tolerated. Taken 
together with data from the Sorafenib Hepatocellular Carcinoma Assessment 
Randomised Protocol (SHARP) trial, sorafenib seems to be an appropriate option for 
the treatment of advanced hepatocellular carcinoma. 
Rajarajan, R. (2009) To develop film coated tablets of B-complex vitamins 
with amino acids and minerals with various polymers by trial and error method. The 
excipients were selected to control of moisture uptake from environment; film coating 
approach was used seal coat followed film coating using commercially available 
OPADRY AMB as a coating polymer. Selected formulations were subjected to 
accelerated stability study. Trial batch formulations were having better release which 
is having excipients of less-hygroscopicity. Formulation was found stable by using 
less hygroscopic excipients with super disintegrents. The film coating was effective 
with initial seal coat followed by film coating with OPADRY AMB as a film coating 
polymer. The accelerated stability of the formulation was found satisfactory. 
Ambrosini, G., et al. (2008) report Tumor cells were treated with Sorafenib 
and examined for growth inhibition, inhibition of phosphor kinases, cell cycle arrest. 
A review of this literature confirms the minimum concentration of Sorafenib required 
inhibiting the growth of tumours. 
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Preetha, B., et al. (2008) The effect of mode of incorporation of 
superdisintegrants like croscarmellose sodium, sodium starch glycolate and 
crospovidone (polyplasdone XL and XL-10) on dissolution of three model drugs with 
varying aqueous solubility, like carbamazepine (poorly soluble), acetaminophen 
(sparingly soluble) and cetrizine HCl (Soluble) from their respective tablet 
formulations prepared by wet granulation was studied. The disintegrants were 
incorporated extragranularly or intragranularly or distributed equally between the two 
phases. The results indicated that Crospovidone in general was effective in improving 
the dissolution of the drugs used in the study and generally extragranular mode of 
addition seemed to be the best mode of incorporation, irrespective of the solubility of 
the main tablet component. 
Sebastien, H. (2007) report a case of adult clear-cell RCC with extensive 
rhabdoid features treated with the tyrosine kinase inhibitor Sorafenib. A review of the 
literature summarizes important aspects of this malignancy. They discussed clinical 
and histological findings as well as the patient‟s response to Sorafenib therapy. A 
review of the literature confirms that adult rhabdoid RCC is a rare but aggressive 
tumour with a distinctly poor prognosis. In patient, Sorafenib appeared to confer 
prolonged disease stabilization. 
Sanghvi, P., et al. (2003) Investigate the effect of sodium lauryl sulfate (SLS) 
as an ingredient of dissolution media on the disintegration and dissolution of 
immediate release (IR) tablets containing cellulose derivative disintegrants using USP 
dissolution apparatus 2 tester. To develop alternative dissolution test methods for such 
tablets by employing different surfactants and dissolution apparatus. Conclusion was 
Dissolution media containing SLS can significantly hinder the disintegration of tablets 
containing cellulose-based disintegrants resulting in a very slow dissolution rate. 
Other surfactants, ionic and nonionic, did not exhibit this effect.
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5. DRUG AND EXCIPIENTS PROFILE 
5.1. DRUG PROFILE:  
 ( http://en.wikipedia.org/wiki/sorafenib ) 
Name of the drug               : Sorafenib  
Description                        : White to pale yellow in colour 
State                                    : Solid 
Molecular formula             : C21H16ClF3N4O3 
Molecular Weight              : 464.825 
Chemical Structure             : 
                                                         
IUPAC Name : 4-[4-[[4-chloro-3-(trifluoromethyl) phenyl] carbamoylamino]  
                                 Phenoxy –N-methyl pyridine-2-carboximide   
Solubility  :  Soluble in PEG,Slightly soluble in ethanol and Insoluble    
                                  in  water 
Melting Point  : 230ºC 
Taste & Odour : Tasteless ,  Odourless 
Absorption  : Absorbed through GI tract 
Protein binding : 99.5 % 
Half life  : 25-48 hrs 
Clearance  : 1280 ±67 ml/min. 
Cmax   : 12.5 μ mol/l 
Tmax   : 4 hrs 
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Bioavailability  : 29-49 % 
5.1.1. Pharmacological Nature of Sorafenib 
Indication: It is a kinase inhibitor indicated for the treatment of 
• Hepatocellular carcinoma. 
• Advanced renal cell carcinoma. 
5.1.2. Mechanism of action:                                             (Ahmad, T., et al., 2004) 
  Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. 
Sorafenib was shown to inhibit multiple intracellular (CRAF, BRAF and mutant 
BRAF) and cell surface kinases (VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-ß). 
Several of these kinases are thought to be involved in tumor cell signaling, 
angiogenesis, and apoptosis. Sorafenib inhibited tumor growth and angiogenesis of 
human hepatocellular carcinoma and renal cell carcinoma 
5.1.3. Pharmacokinetic Nature of Sorafenib 
5.1.3.1. Absorption  
                 Following oral administration, sorafenib reaches peak plasma levels in 
approximately 3 hours. When given with a moderate-fat meal, bioavailability was 
similar to that in the fasted state. With a high-fat meal, sorafenib bioavailability was 
reduced by 29% compared to administration in the fasted state. It is recommended 
that NEXAVAR be administered without food (at least 1 hour before or 2 hours after 
eating) Mean Cmax and AUC increased less than proportionally beyond doses of 400 
mg administered orally twice daily.  
5.1.3.2. Distribution 
                  In vitro binding of Sorafenib to human plasma proteins is 99.5%. Human 
serum albumin, α-globulin and the low density lipoproteinare the main binding 
proteins. Sorafenib was equally distributed between plasma and blood cells.The 
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binding of Sorafenib to plasma dependant on pH. The fraction unbound decreased to 
0.165% at pH7.99 and increased to 1.80% at acidic pH 6.78. 
5.1.3.3. Metabolism  
                  Sorafenib is metabolized primarily in the liver, undergoing oxidative 
metabolism, mediated by CYP3A4, as well as glucuronidation mediated by UGT1A9. 
Sorafenib accounts for approximately 70-85% of the circulating analytes in plasma at 
steady-state. Eight metabolites of sorafenib have been identified, of which five have 
been detected in plas N-oxide, shows in vitro potency similar to that of sorafenib. This 
metabolite comprises approximately 9-16% of circulating analytes at steady-state.  
5.1.3.4. Excretion 
                  Following oral administration of a 100 mg dose of a solution formulation 
of sorafenib, 96% of the dose was recovered within 14 days, with 77% of the dose 
excreted in feces, and 19% of the dose excreted in urine as glucuronidated 
metabolites. Unchanged sorafenib, accounting for 51% of the dose, was found in 
feces but not in urine. 
5.1.4. Drug Interactions: 
• Docetaxel : Caution, Docetaxel AUC increases when co-administered with Nexavar. 
•Doxorubicin:Caution,doxorubicin AUC increases when co-administered with 
Nexavar. 
•Fluorouracil:Caution,fluorouracil AUC changes when co-administered with Nexavar. 
5.1.5. Side effects: 
 Diarrhoea 
 Rash/Desquamation 
 Fatigue 
 Anemia 
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 Hand/Foot Skin Reaction 
 Alopecia 
 Nausea 
 Pruritus 
 Anorexia 
 Hemorrhage 
5.1.6. Dosing and administration: 
                 400 mg (2 tablets) orally twice daily without food. Treatment interruption 
and/or dose reduction may be needed to manage suspected adverse drug reactions. 
Dose may be reduced to 400 mg once daily or to 400 mg every other day. 
5.2. EXCIPIENTS PROFILE 
5.2.1. Excipients:  
Substances, other than the active ingredient, which have been appropriately evaluated 
for safety and are included in a drug delivery system to provide support. The 
excipients used must have following characteristics- 
1. They must be stable both physically, chemically and biologically inactive. 
2. It must be free from microbial contamination 
3. Excipients used in tablet formulation must be accepted by regulatory agencies and 
should meet  the entire current regulatory requirement. 
5.2.1.1. Types of excipients: 
Binders: 
Binders hold the ingredients in a tablet together. Binders ensure that tablets 
and granules can be formed with required mechanical strength, and give volume to 
low active dose tablets. 
Example: microcrystalline cellulose, sucrose, lactose 
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Fillers and diluents: 
Fillers fill out the size of a tablet or capsule, making it practical to produce and 
convenient for the consumer to use. By increasing the bulk volume, the fillers make it 
possible for the final product to have the proper volume for patient handling. 
Example: mannitol, sorbitol, calcium carbonate,  
Lubricants: 
Lubricants prevent ingredients from clumping together and from sticking to 
the tablet punches or capsule filling machine. Lubricants also ensure that tablet 
formation and ejection can occur with low friction between the solid and die wall 
Example:  magnesium stearate 
Colours: 
Colours are added to improve the appearance of a formulation. Colour 
consistency is important as it allows easy identification of a medication. 
Glidants: 
Glidants are used to promote powder flow by reducing interparticle friction 
and cohesion. These are used in combination with lubricants as they have no ability to 
reduce die wall friction. 
Example:  talc and magnesium carbonate 
Flavours: 
Flavours can be used to mask unpleasant tasting active ingredients and 
improve the likelihood that the patient will complete a course of medication. 
Disintegrants: 
Disintegrants expand and dissolve when wet causing the tablet to break apart 
in the digestive tract, releasing the active ingredients for absorption. 
Example: sodium starch glycolate, croscarmellose sodium 
Formulation and evaluation of Sorafenib tosylate         Drug & excipients profile 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur  Page 44 
 
Antiadherents: 
Antiadherents are used to reduce the adhesion between the powder (granules) 
and the punch faces and thus prevent sticking to tablet punches. 
Example: magnesium stearate 
I. Microcrystalline Cellulose 
   1 Nonproprietary Names: 
      BP: Microcrystalline cellulose 
      IP: Microcrystalline cellulose 
      PhEur: Cellulosum microcristallinum 
      USPNF: Microcrystalline cellulose 
2.Synonyms: 
Avicel PH, Celex, cellulose gel, Celphere, Ceolus KG, crystalline cellulose, E460,   
Emcocel, Ethispheres, Fibrocel, Pharmacel, Tabulose, Vivapur. 
3.Description: 
  Microcrystalline cellulose is purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous 
particles. It is commercially available in different particle sizes and moisture grades 
that have different properties and applications 
4.Empirical Formula and 
 Molecular Weight                  : (C6H10O5)n ≈36 000 where n ≈ 220. 
5.Molecular structure: 
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6.Functional Category: 
  Adsorbent; Suspending agent; as a Diluent in tablets and capsules; tablet 
disintegrant. 
7.Solubility:  
Slightly soluble in 5% w/v Sodium hydroxide solution, practically insoluble in water, 
diluent acids  and most organic solvents. 
8.Incompatibilities:  
  Microcrystalline cellulose is incompatible with strong oxidizing agents. 
9.Stability and storage conditions:  
  Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material  should be stored in a well-closed container in a cool, dry place. 
10.Applications in Pharmaceutical Formulation or Technology: 
  Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet 
granulation and direct-compression processes. In addition to its use as a 
binder/diluent, microcrystalline cellulose also has some lubricant and disintegrates 
properties that make it useful in tableting. Microcrystalline cellulose is also used in 
cosmetics and food products. 
II. Sodium Starch Glycolate (SSG) 
1. Synonyms:  
 Explotab; Primogel; Vivastar. Carboxymethyl starch, sodium salt. 
2. Chemical Name: 
 Sodium carboxymethyl starch 
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3. Description:  
                It is a white or almost white free-flowing very hygroscopic powder. The 
PhEur states that when examined under a microscope it is seen to consist of: granules 
irregularly shaped, ovoid or pear-shaped, 30–100 mm in size, or rounded,10–35 mm 
in size; compoundgranules consisting of 2–4 components occur occasionally; the 
granules have an eccentric hilum and clearly visible concentric striations. Between 
crossed nicol prisms, the granules show a distinct black cross intersecting at the 
hilum; small crystals are visible at the surface of the granules. The granules how 
considerable swelling in contact with water. 
4. Functional Category:  
     Tablet and capsule   disintegrate. 
5. Solubility:  
      Practically insoluble in water and insoluble in most organic solvents. 
6. Incompatibilities:  
     Sodium starch glycolate is incompatible with ascorbic acid. 
7. Stability and Storage Conditions:  
              Tablets prepared with sodium starch glycolate have good storage properties. 
Sodium starch glycolate is stable although very hygroscopic, and should be stored in a 
well-closed container in order to protect it from wide variations of humidity and 
temperature, which may cause caking. The physical properties of sodium starch 
glycolate remain changed for up to 3 years if it is stored at moderate temperatures and 
humidity. 
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8. Applications in Pharmaceutical Formulation : 
              Sodium starch glycolate is widely used in oral pharmaceuticals as a 
disintegrant in capsule and tablet formulations. It is commonly used in tablet prepared 
by either direct compression or wet granulation processes. 
III. Crospovidone 
1. Nonproprietary Name:  
 Crospovidone. 
2. Synonyms: 
 Crospovidonum;   Polyplasdone XL;  Poly vinyl poly pyrrolidone. 
3. Chemical Name:  
   1-Ethenyl-2-pyrrolidinone homopolymer 
4. Description:  
              Crospovidone is a white to creamy-white, finely divided, free flowing, 
practically tasteless, odorless or nearly odorless, hygroscopic powder. 
5.  Empirical Formula and Molecular Weight: 
   (C6H9NO) n, 2.500 - 2.5000.000 g·mol
−1
  
6. Molecular structure: 
                                         
7. Functional Category: 
  Tablet disintegrant 
8. Solubility:  
  Practically insoluble in water and most common organic solvents. 
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9. Stability and Storage Conditions: 
    Since crospovidone is hygroscopic, it should be  stored in an airtight container 
in a cool, dry place 
10.  Incompatibilities: 
  Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular 
adduct with some materials. 
11. Applications: 
  Crospovidone is a water-insoluble tablet disintegrant and dissolution agent 
used at 2-5 % concentration in tablets prepared by direct compression or wet- and dry-
granulation methods. It can also be used as a solubility enhancer. 
12. Related Substances: 
  Crospovidone, povidone. 
IV. Sodium Lauryl Sulphate (SLS) 
1. Synonyms:  
  Dodecyl sodium sulphate; Elfan 240 
2. Description:  
  White cream to pale yellow coloured crystals, bitter in taste. 
3. Empirical Formula: C12H25NaO4S 
4. Molecular Weight: 288.37 
5. Functional Category: Anionic surfactant; detergent; emulsifying agent; skin 
penetrant; tablet and capsule lubricant; disintegrant, wetting agent. 
6. Molecular structure: 
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7. Solubility:  
  Freely soluble in water forming opalescent solution, practically insoluble in 
chloroform, ether. 
8. Incompatibilities:  
  Incompatible with strong oxidizing agents. 
9. Applications in Pharmaceutical Formulation or Technology: 
             Sodium Lauryl Sulphate is widely used in oral pharmaceuticals as a 
disintegrant in capsule and tablet formulations. It is commonly used as emulsifier, 
detergent, topical application, tablet lubricant & wetting agent in dentifrices It is 
commonly used in tablet prepared by either direct compression or wet granulation 
processes. 
10. Storage conditions: 
  Should be stored in well-closed container, in a cool & dry place. 
V. Magnesium Stearate 
1. Nonproprietary Names: 
     BP: Magnesium stearate 
  IP: Magnesium stearate 
  PhEur: Magnesii stearas 
  USPNF: Magnesium stearate 
2. Synonyms: 
  Magnesium octadecanoate; octadecanoic acid; magnesium salt; stearic acid. 
3. Chemical Name :  
  Octadecanoic acid magnesium salt 
4. Empirical Formula: Mg(C18H35O2)2 
5. Molecular Weight: 591.27 g/mol 
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6. Molecular structure:  
                                          
7. Functional Category: Tablet and capsule lubricant. 
8. Description: 
              Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. The powder is greasy to the touch and readily adheres to the skin. 
9. Solubility:  
  Practically insoluble in ethanol (95%), ether and water; slightly soluble in 
warm benzene and warm ethanol (95%). 
10. Incompatibility:  
       Incompatible with strong acids, alkalis and iron salts. Avoid mixing with 
strong oxidizing materials. Magnesium Stearate cannot be used in product containing 
aspirin, some vitamins and most alkaloidal salts. 
11. Storage conditions: 
  Should be stored in well-closed container, in a cool & dry place. 
12. Applications in Pharmaceutical Formulation or Technology: 
  Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams. 
VI. Croscarmellose Sodium 
1. Nonproprietary Name: 
  Croscarmellose sodium 
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2. Synonyms: 
   Carmellosum natricum conexum; Crosslinked carboxy methyl cellulose 
sodium; Explocel:modified cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; 
Solutab; Vivasol 
3. Chemical Name: 
  Cellulose, carboxy methyl ether, sodium salt. 
4. Functional Category: 
  Tablet and capsule disintegrant. 
5. Description: 
  Croscarmellose sodium occurs as an odorless, white or grayish-white powder. 
6. Solubility:  
  Insoluble in water, although Croscarmellose sodium rapidly swells to 4-8 
times its original volume on contact with water. Practically insoluble in acetone, 
ethanol and toluene. 
7. Stability and Storage Conditions:  
  Croscarmellose sodium is a stable though hygroscopic material. A model 
tablet formulation prepared by direct compression, with Croscarmellose sodium as a 
disintegrant, showed no significant difference in drug dissolution after storage at 
300
0
C for 14 months. Croscarmellose sodium should be stored in a well closed 
container in a cool, dry place. 
8. Incompatibilities:  
      The efficacy of disintegrant such as Croscarmellose sodium, may be slightly 
reduced in tablet formulations prepared by either the wet-granulation or direct 
compression process that contain hygroscopic excipients such as sorbitol. 
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Croscarmellose Sodium is not compatible with strong acids or with soluble salts of 
iron and some other metals such as aluminum, mercury and zinc. 
9. Applications:  
  Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for capsules, tablets and granules. In tablet formulations, Croscarmellose 
sodium may be used in both direct-compression and wet-granulation processes. When 
used in wet granulations, the Croscarmellose sodium should be added in both the wet 
and dry stages of the process (intra and extra- granularly) so that the wicking and 
swelling ability of the disintegrant is best utilized. Croscarmellose sodium at 
concentrations up to 5% w/w may be used as tablet disintegrant, although normally 
2% w/w is used in tablets prepared by direct compression and 3%w/w in tablet 
prepared by wet granulation process. 
VII. Hydroxypropyl Methyl Cellulose (HPMC) 
1. Non-proprietary names: 
IP: Hydroxypropylmethylcellulose 
BP: Hypromellose 
Ph Eur: Methylhydroxypropylcellulosum 
USP: Hypromellose 
2. Chemical Name: Cellulose, 2-hydroxypropyl methyl ether 
3. Synonyms:  
  Methyl Hydroxy Propyl cellulose; Propylene Glycol ether of methylcellulose;  
Culminal HPMC. 
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4. Structural Formula: 
                                          
 
5. Molecular weight: 10,000 - 15,00,000 
6. Color: White to creamy-white 
7. Nature: Fibrous or granular powder 
8. Solubility:  
  Soluble in cold water, practically  insoluble in Chloroform, ethanol (95%) and 
ether but Soluble in mixture of ethanol and Dichloromethane. 
9. Functional Category:  
 Used as Coating agent, film-forming, rate-controlling polymer for sustained 
release, stabilizing agent, suspending agent, tablet binder, viscosity-increasing agent. 
10. Applications: 
  In oral product HPMC is primarily used as tablet binder. Concentration 
between 2-5% w/w may be used as a binder in either wet or dry granulation process. 
HPMC is widely used in oral and topical pharmaceutical formulation. Concentration 
of 0.45-1% w/w may be added as a thickening agent to vehicle for eye drop and 
artificial tear solution. HPMC is used as an adhesive in plastic bandage and as a 
wetting agent for hard contact lenses. It is widely used in cosmetics and food 
products. In addition, HPMC is used as an emulsifier, suspending agent and 
stabilizing agent in topical gels and ointments. As a protective colloid, it can prevent 
droplets and particle from coalescing or agglomerating thus, inhibiting the formation 
of sediments. 
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11.Stability and storage:  
        It is stable although it is slightly hygroscopic. The bulk material should be 
stored in an airtight container in a cool and dry place. Increased in temperature 
reduces the viscosity of the solution. 
12.Safety:                                                                         .(Raymond, C.R. et al., 2009 ) 
  It is generally regarded as a non-toxic and non-irritant material, so it is widely 
used in many oral and topical pharmaceutical formulations. Excessive consumption of 
HPMC may have laxative effect 
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5.3. INNOVATOR PROFILE: 
(http://www.rxlist.com/nexavar-drug.hmt) 
PRODUCT NAME                       :       Nexavar, BAY 43-9006, Sorafenibum,                                       
                                                                 Kinome-766.            
LABEL CLAIM                            :       Each tablet contains 200 mg of sorafenib 
MANUFACTURED BY               :       Bayer health care 
DESCRIPTION          :     Red in colour, debossed with bayer cross on   
                                                                one side and 200 on other side.                                                                                                                                                                                                                
INACTIVE 
 INGREDIENTS                    :       microcrystalline cellulose, 
     croscarmellose sodium, 
     hydroxy propyl methyl cellulose, 
     magnesium stearate. 
THICKNESS                                 :       4.44 mm 
WIDTH                                          :       7.64 mm 
DIAMETER                                  :       10.05 mm 
STORAGE                                     :        Store at 25˚C (77˚F) 
DISSOLUTION  
APPARATUS                                 :        Paddle type(USP apparatus II) 
DISSOLUTION MEDIUM           :       0.1M Hydrochloric acid with 
                                                                     1%SLS. 
DISSOLUTION  
VOLUME                                         :               900 ml 
 
TIME POINTS                                 :         5, 10, 15, 20, 30 minutes 
SPEED                   :          75 rpm 
  
 
 
 
 
 
 
 
 
 
MATERIALS 
AND  
EQUIPMENTS  
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6. MATERIALS 
6.1. MATERIALS USED 
Table  6.1: List of raw materials used in the formulation 
S.No Ingredients Manufacturer Category 
1. Sorafenib tosylate NATCO Pharma Ltd, 
Hyderabad. 
Active                
pharmaceutical         
ingredients 
2. Micro crystalline 
Cellulose 
FMC Bio polymer,  
Newyork. 
Diluent 
3. Sodium Lauryl Sulfate Ferro Corporations, USA Ferro Surfactant 
4. CrosCarmellose sodium Ferro Corporations,Ireland.  Disintegrant 
5. HPMC E-5 DMV Fonterra Excipients, 
Hyderabad. 
Binder 
6. Sodium starch glycolate DMV Fonterra Excipients, 
Hyderabad. 
Disintegrant 
7. CrosPovidone M/S Isp Technology , 
USA. 
Disintegrant 
8. Magnesium Stearate Luzenac valchisone, Italy Lubricant 
9. Purified water NATCO Pharma Ltd, 
Hydreabad. 
Solvent 
10. Advantia prime pink Ferro industriasquimicas, 
Portugal 
Colouring agent 
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                                                   6.2. INSTRUMENTS 
6.2 INSTRUMENTS: 
Table no 6.2: List of instruments used for the formulation 
S.No Name of instrument Model no. Make 
1. Electronic Weighing Balance PR 203 Mettler 
Toledo,Mumbai 
2. Tap Density Tester USP ETD-1020 Electro lab,Mumbai 
3. Electronic Moisture Analyzer HG 63 Mettler Toledo 
4. Tablet Compression Machine-8 
Station 
MINI Press - II MT Rimek,Mumbai. 
5. Digital Hardness Tester TH 10503 Labindia,Hyderabad 
6. Disintegration Test Apparatus 
USP 
ED-2AL Electro lab,Mumbai. 
7. Friabilator USP EF-2 Electro lab,Mumbai. 
8. Mechanical Stirrer RQT-127D Remi Motors,Mumbai. 
9. Pharma R&D Coater Deluxe Ideal Cures,Mumbai. 
10. Fluid Bed Drier UT-150 Umang Pharmatech 
11. Rapid mixture granulator RMG 25 Anchor mark,Mumbai. 
12. Multi Mill MM 15 Anchor mark,Mumbai. 
13. Tray Drier PPT TD6 Platinum Pharmatech 
14. Dissolution Test Apparatus Type II UV-Pharmaspec– 1700 DBK Instruments Ltd., 
Mumbai. 
 
  
 
 
 
 
 
 
 
 
EXPERIMENTAL 
WORK 
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7. EXPERIMENTAL WORK 
7.1. Preformulation Studies 
                  Preformulation studies are performed to investigate the physical and 
chemical properties of a drug substance alone and also when combined with other 
substance such as excipients. It is the first step in the rational development of dosage 
forms.    
Objective: 
  The overall objective of preformulation testing is to generate information 
useful to the formulation in developing stable and bioavailable dosage forms. 
Scope:               
The use of preformulation parameters maximizes the chances in formulating 
an acceptable, safe, efficacious and stable product and at same time provides the basis 
for optimization of the drug product quality.   
7.1.1. Identification of Drug: 
7.1.1.1. Identification of drug by HPLC method:             (Krefeld,Germany)                   
In the Assay, the principal peak in the chromatogram obtained with the test solution 
corresponds to the peak in the chromatogram obtained with the reference solution. 
7.1.2. Organoleptic Properties: 
The color, odor and taste of the drug were recorded using descriptive terminology. 
7.1.3. Solubility Study:                                                                              (IP,2007)                                          
 
              It is important to know about solubility characteristic of a drug in aqueous 
system, since they must possess some limited aqueous solubility to elicit a therapeutic 
response. The solubility of drug was recorded by using various descriptive 
terminology specified in Indian pharmacopoeia, 2007. 
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7.1.3.1. Solubility specification: 
Table 7.1: The solubility specifications 
Descriptive terms. 
Approximate volume of solvent in 
milliliters per gram of solvent. 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 1 to 30 
Sparingly soluble From 30to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 100 to 10,000 
Practically insoluble More than 10,000 
 
7.1.4. Preparation of standard curve: 
7.1.4.1. Linearity: 
             The linearity of the response for Sorafenib tosylate was determined by 
preparing suitable dilutions were made 10-50µg/ml from standard stock solution. All 
the solutions were injected and the chromatograms were recorded at 265 nm. The 
above concentration range was found to be linear and obeys Beer‟s law. The 
procedure was repeated for three times. The peak areas were plotted against 
concentration and the calibration curve was constructed. 
7.1.5. Determination of Drug-Excipient Compatibility: 
           A Compatibility study focuses on a binary mixture of drug substance and some 
selected excipients in a fixed ratio with or without added moisture. The mixture is 
stored at elevated temperature 40˚ C±2˚C/75%±5%RH, 25˚C± 2˚C/60%±5%RH in 
capped vials. The result of the interaction between the active drug and excipients is 
determined by HPLC. 
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7.1.5.1. Procedure: 
 Drug and Excipients mixture shall be prepared based on the information from 
Physician Desk Reference (PDR). 
 The Drugs and Excipients individually and in combination shall be subjected for 
accelerated study conditions along with control samples and study at fixed intervals. 
 The recommended drug- excipients ratios for solid dosage forms are tabulated 
below 
           Table 7.2:  Drug excipient ratios for solid dosage forms: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name of 
Excipient 
Quantity of Drug in mg 
< 5 mg 
5  
10mg 
10  
50mg 
50  
200mg 
200  
500mg 
500 mg 
Fillers & 
Diluents 
1:40 1:20 1:10 1:5 1:2 1:1 
Disintegrates / 
Polymers 
1:10 1:5 1:1 1:1 1:0.5 1:0.25 
Binders 1:10 1:5 1:1 1:0.5 1:0.25 1:0.1 
Lubricants 1:0.5 1:0.5 1:0.25 1:0.1 1:0.05 1:0.05 
Coating  agents 1:5 1:5 1:1 1:0.5 1:0.25 1:0.1 
Colours / 
Sweetners 
1:0.05 1:0.05 1:0.05 1:0.05 1:0.05 1:0.05 
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7.1.5.2 . Related Impurities (HPLC method): 
Instuments: High performance liquid chromatograph equipped with UV-Detector 
and Data Handling system. 
7.1.5.2.1. Apparatus: 
• Analytical balance 
• Volumetric flasks 
• Pipettes 
• 0.22µm membrane filter 
• Filteration unit 
• 0.22µm PVDF filter 
• pH meter 
7.1.5.2.2. Chemicals and Reagents: 
• Sorafenib working standard 
• Potassium dihydrogen Orthophosphate  
• Orthophosphoric acid- HPLC grade 
• Methonol- HPLC grade 
• Tetrahydrofuran 
• Acetonitrile- HPLC grade 
• Purified water- Milli-Q-grade 
• Impurity A working standard 
• Impurity B working standard 
• Impurity C working standard 
7.1.5.2.3 Chromatographic conditions: 
• Column- X-Terra RP- 18 (100 x 4.6mm), 5µm 
• Flow rate – 2.0ml/ minute 
• Wavelength- UV-293nm 
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• Column temperature- 30ºC 
• Injection volume- 10µl 
• Run time- 45 minutes 
7.1.5.2.4 Preparations: 
 Phosphate buffer preparation: 
                 2.72 g of potassium dihydrogen orthophosphate was weighed and 
transferred in to 1000 ml of purified water and mix. Adjust the solution pH to 3.0 with 
orthophosphoric acid. 
Mobile phase-A Preparation: Buffer preparation was used as mobile phase-A ,it was 
filtered through 0.22µm membrane filter and degassed. 
Mobile phase-B preparation: 
                 Mixture of  Acetonitrile and Tetrahydrofuran in the ratio of 90:10 v/v was 
prepared and the solution was filtered through 0.22µm membrane filter and degassed. 
Diluent preparation: 
   Prepare a filtered and degassed mixture of Methanol and Acetonitrile in the ratio of 
50:50 v/v respectively. 
Placebo preparation: 
Placebo powder equivalent to 200 mg of Sorafenib was weighed accurately and 
transferred into 200 ml volumetric flask and added with 160 ml of dilution medium 
and sonicated for 20 minutes with occasional shaking .The solution was cooled to 
room temperature and the volume was made and filtered through 0.22 µm membrane 
filter and degassed. 
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Peak Identification solution preparation: 
About each 5.0 mg of Impurity-A ,Impuity-B, Impurity-C was accurately weighed 
and transferred into a 50 ml volumetric flask, added with 30 ml of dilution medium 
and sonicated to dissolve .The solution was cooled and the volume was made. 
 137.0 mg of Sorafenib tosylate working standard 
(equivalent to 200mg ot Sorafenib) was weighed and transferred into 200 ml 
volumetric flask,160 ml of dilution medium was added and sonicated for 20 mintues 
with occasional shaking. The resulting solution was cooled room temperature, added 
with 2.0 ml of peak identification solution and the volume dilute to mark diluents 
medium. 
Standard preparation: 
              20mg equivalent of Sorafenib tosylate working standard was accurately 
weighed and transferred into 200ml of volumetric flask add about 160ml of 
dissolution medium and sonicated to dissolve. Solution  was cooled to room 
temperature and volume was made to mark with dilution medium 
 1ml of the standard preparation transferred into a 
100ml volumetric flask and made with dilution medium. 
Sample preparation: 
               20 tablets of Sorafenib was powered and transferred an accurately weighed 
portion of the powder, equivalent to 200mg of Sorafenib into a 200 ml volumetric 
flask. Add about 160ml of dilution medium . Sonicated for 20 minutes with 
occasional shaking. The solution was cooled to room temperature volume was made 
upto 200ml and filtered through0.22µm PVDFfilter. 
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7.1.5.2.5 System suitability: 
                 The standard preparation (Six replicate injections),and Peak identification 
solution(one injection) was chromatogramed and the peak area responses for the 
analyte peak and evaluate the system suitability parameters as directed. 
7.1.5.2.6 Acceptance criteria: 
%RSD for replicate injections of peak area response of the Sorafenib peak 
from the standard preparation should be not more than 10.0 
The Tailing factor for Sorafenib peak should be not more than 2.0 
The number of Theoretical plates for Sorafenib peak should be not less than 2000. 
7.1.5.2.7. Procedure: 
                   10µl of  placebo preparation , peak identification solution preparation, 
diluent as blank, standard preparation and sample preparation are injected  seperatly 
into the chromatograph, and  the chromatograms recorded and %  of each impurity in 
the portion of Sorafenib tablets was calculated using the formula 
7.1.5.2.8 Calculation: 
%  known impurities:  
𝐼𝐴
𝑆𝐴
𝑋
𝑆𝑊
200
𝑋
1
100
𝑋
200
𝑇𝑊
𝑋
𝑃
100
𝑋
  464.825    × 𝐴𝑣𝑔. 𝑊𝑡
63 .040            𝐿𝐴
𝑋100/𝑅𝑅𝐹 
% Unknown impurities:  
𝑈𝐴
𝑆𝐴
𝑋
𝑆𝑊
200
𝑋
1
100
𝑋
200
𝑇𝑊
𝑋
𝑃
100
𝑋
  464.825    × 𝐴𝑣𝑔. 𝑊𝑡
63 .040            𝐿𝐴
𝑋100/𝑅𝑅𝐹 
 
Where, 
UA- Peak area response due to Unknown impurity from Sample preparation 
IA- Peak area response due to known impurity from Sample preparation 
SA- Peak area response due to Sorafenib from Standard preparation 
SW- Weight of Sorafenib working Standard taken in mg. 
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TW- Weight of sample taken in mg 
P- Purity of Sorafenib working standard, taken on as is basis. 
Avg Wt-  Average weight of tablet. 
LA-  Label Amount 
RRF-Relative response factor of respective known impurity. 
 
   7.1.6 Differential scanning calorimetry:       
            Any possible drug excipients interaction can be studied by thermal analysis. 
The DSC analysis of pure drug, drug +CCS,  drug + SLS  were carried out using 
Shimadzu to evaluate any possible drug-excipient  interaction. The 2 mg sample were 
heated in a hermetically sealed aluminum pans in the temperature range of 25-300ºC 
at heating rate of 10ºC /min under nitrogen flow of 30 ml/min.  
7.1.7. Loose Bulk Density (LBD)                                        (Lachman L.,et al.,1991)
 
              An accurately weighed powder blend from each formula was lightly shaken 
to break any agglomerates formed and it was introduced in to a measuring cylinder. 
The volume occupied by the powder was measured which gave bulk volume. The 
loose bulk density (LBD) of powder blends was determined using the following 
formula. 
Loose bulk density = Total weight of powder / Total volume of powder 
 7.1.8. Tapped bulk density (TBD)                                    (Lachman L.,et al.,1991) 
               An accurately weighed powder blend from each formula was lightly shaken 
to break any agglomerates formed and it was introduced into a measuring cylinder. 
The measuring cylinder was tapped until no further change in volume was noted 
which gave the tapped volume.  
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The tapped bulk densities (TBD) of powder blends were determined using the 
following formula. 
   Tapped bulk density= Total weight of powder / Total volume of tapped powder 
7.1.9.  Hausner’s Ratio:                                                     (Lachman L.,et al.,1991) 
                         Hausner‟s ratio was determined by following equation,    
Hausner‟s Ratio = Tapped bulk density/Loose bulk density 
  A hausner ratio less than 1.25 indicates good flow while greater than 1.5 indicates 
poor flow. 
7.1.10. Carr’s Compressibility Index:                              (Lachman L.,et al.,1991)      
                It is a simple index that can be determined on small quantities of powder. In 
theory, the less compressible a material the more flowable it is. The compressibility 
indices of the powder blends was determined using formula, 
Carr‟s Compressibility Index (%) = [(TBD-LBD)/ TBD] x100 
Relationship   between % compressibility and flowability is shown in the table 7.2. 
Table 7.3: Standard values of Carr‟s index 
S. No. Carr‟s index Type of flow 
1 5-15 Excellent 
2 12-16 Good 
3 18-21 Fair to passable 
4 23-35 Poor* 
5 33-38 Very poor* 
6 >40 Extremely poor* 
                        * May be improved by glidant 
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 7.1.11. Angle of repose                                                (LachmanL.,et al.,1991) 
The angle of repose was determined by the funnel method. The accurately 
weighed powder was taken in a funnel. The height of the funnel was adjusted in such 
a way that the tip of the funnel just touched the apex of the heap of the powder. The 
powder was allowed to flow through the funnel freely onto the surface. The diameter 
of the powder cone was measured. The angle of repose was calculated using the 
following equation. 
                                     tan 𝜃  =
ℎ
𝑟
 
Where „h‟ and „r‟ are the height and radius respectively of the powder cone 
 
                    Table 7.4:  Standard values of angle of repose (θ) 
S. No. Flowability  Angle of repose  
1 Excellent <25 
2 Good 25-30 
3 Passable* 30-40 
4 Poor 37-45 
5 Very poor >45 
 * Adding glidant for improving flow 
7.2. METHODOLGY 
7.2.1. Formulation of Sorafenib Tosylate 200 mg tablets 
7.2.1.1. Formulation Planning: 
The immediate release tablets containing 200mg sorafenib tosylate were prepared 
with a total tablet weight of 400mg.  
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7.2.1.2. Manufacturing Procedure: 
• Micro crystalline cellulose, cross Carmellose sodium, sodium lauryl Sulphate were 
weighed and   sifted through 40 mesh. 
• To the above blend sorafenib tosylate was added and sifted through 18 mesh. 
• The sifted material was placed in cantabin blender and mixed for 8, 10, 12 min. 
• Dry mix samples were taken at respective time points for content uniformity. 
• Hypromellose E5 was dissolved in purified water and above was granulated 
• The wet mass passed through 12 mesh and dried in tray dryer at 600C. 
• The dried granules were passed through 18 mesh. 
• Crosscarmellose, magnesium Stearate were weighed and sifted through 40 mesh. 
• To the dried granules lubricated blend was added and placed in cantabin blender. 
• The lubricated blend was compressed using 10 mm round punches. 
Film coating:  
10% coating solution is used .weight gain is 10 mg / tablet. 
Coating solution composition: 
 Advantia prime pink, Hypromellose, Titanium dioxide, Ferric oxide, poly 
ethylene glycol. 
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7.2.1.3. Formulation of Sorafenib tosylate immediate release tablets  
        Table 7.5: Composition of sorafenib tosylate immediate release tablets 
 
Ingredients 
 
F1 
(mg) 
 
F2 
(mg) 
 
F3 
(mg) 
 
F4 
(mg) 
 
F5 
(mg) 
 
F6 
(mg) 
 
F7 
(mg) 
 
F8 
(mg) 
 
F9 
(mg) 
Sorafenib 
Tosylate 
274 274 274 274 274 274 274 274 274 
Microcrstalline 
cellulose 
75.3 65.3 61.4 57.5 57.5 53.6 49.7 64.5 48.5 
Sodium lauryl 
sulphate 
- - 3.9 7.8 7.8 11.7 15.6 7.8 7.8 
CrosCarmellose 
sodium 
39.0 39.0 39.0 - 39.0 39.0 39.0 32.0 48.0 
Sodium starch 
glycolate 
- - - 39.0 - - - - - 
Hypromellose E5 7.8 7.8 7.8 7.8 7.8 7.8 7.8 7.8 7.8 
Magnesium 
Stearate 
3.90 3.90 3.90 3.90 3.90 3.90 3.90 3.90 3.90 
Purified Water - q.s q.s q.s q.s q.s q.s q.s q.s 
Advantia prime 
pink 
- 10 10 10 10 10 10 10 10 
Total (mg) 400 400 400 400 400 400 400 400 400 
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7.3. EVALUATION PARAMETERS: 
 Tablet evaluation in immediate release dosage forms may be divided 
conveniently in to following categories    
7.3.1. Appearance:        (Lachman L.,et al.,1991; Bankar G.S. and Rhodes C.T.,1996) 
The tablets were visually observed for capping, chipping, and lamination. 
7.3.2. Physicochemical characteristics:  
 7.3.2.1. Dimension (Thickness )                 (Lachman L.,et al.,1991) 
                 The thickness  of tablets were important for uniformity of tablet size. The 
thickness of the tablets was determined using a Vernier caliper. Three tablets from 
each type of formulation were used and average values were calculated. 
7.3.2.2. Tablet Hardness:        (Lachman L.,et al.,1991; Bankar G.S. and Rhodes 
C.T., 1996) 
For each formulation, the hardness of 6 tablets was determined using the 
Monsanto hardness tester. The tablet was held along its oblong axis in between the 
two jaws of the tester. At this point, reading should be zero kg/cm2. Then constant 
force was applied by rotating the knob until the tablet fractured. The value at this 
point was noted in kg/cm2.  
7.3.2.3. Percent Friability:      (Lachman L.,et al.,1991; Bankar G.S. and Rhodes 
C.T., 1996) 
Friability is the measure of tablet strength. This test subjects a number of 
tablets to the combined effect of shock abrasion by utilizing a plastic chamber which 
revolves at a speed of 25 rpm, dropping the tablets to a distance of 6 inches in each 
revolution. A sample of pre weighed tablets was placed in Roche friabilator which 
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was then operated for 100 revolutions. The tablets were then de dusted and 
reweighed. A loss of less than 1 % in weight is generally considered acceptable. 
Percent friability (% F) was calculated as follows, 
%F =
Initial weight − Final weight
Initial weight
 × 100 
7.3.2.4. Weight Variation                                (IP, 2007; Lachman L.,et al.,1991                         
To find out weight variation 20 tablets of each formulation were weighed                      
individually using an electronic balance, average weight was calculated and 
individual tablet weight  compared with average value to find the deviation in weight.  
Table 7.6:  Specifications of % weight variation allowed in tablets as per Indian 
Pharmacopoeia 
S. No. Average weight of tablets (mg) Maximum percent 
deviation allowed (%) 
1 80 or less 10 
2 More than 80 but less than 250 7.5 
3 More than 250 5 
 
   7.3.3 In-vitro disintegration test  
           The test was carried out on 6 tablets using Tablet disintegration tester.  
Distilled water at 37ºC ± 2ºC was used as a disintegration media and the time in 
seconds taken for complete disintegration of the tablet with no palable mass 
remaining in the apparatus was measured.    
 
 
 
 
Formulation and evaluation of Sorafenib tosylate     Experimental work 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur  Page 72 
 
 
                                             Table 7.7: Specifications 
           Tablet Type Time limit and Specifications 
1. BP 
 Uncoated 
 Coated 
              Film 
             Sugar 
 Gastro resistant, enteric 
 
 Effervescent 
 Soluble 
 Dispersible 
           ,  
 
         <15min 
 
          <30min 
          <60min, repeat in 0.1MHCl 
          >120min in 0.1MHCl 
          <60min in pH 6.8(Phosphate) 
          <5min in 200ml, water, 20°C 
          <3min 
<3min, 2 tablets in 100ml water dispersed 
 
USP 
 Uncoated 
 Plain coated 
 Enteric coated 
 Buccal 
 
<15min  
<30 min  
60min  
    <4hour 
 
7.3.4. Dissolution: 
Dissolution is the process by which a solid solute enters a solution. In the 
pharmaceutical industry, it may be defined as the amount of drug substance that goes 
into solution per unit time under standardized conditions of liquid/solid interface, 
temperature and solvent composition. Dissolution is considered one of the most 
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important quality control tests performed on pharmaceutical dosage forms and is now 
developing into a tool for predicting bioavailability. 
7.3.4.1. Dissolution (by HPLC method): 
7.3.4.2. Instrument(LC 10): High performance liquid chromatography equipped with 
UV-Detector.  
7.3.4.3. Apparatus: 
• Analytical balance 
• Volumetric flasks 
• Pipettes 
• 0.22µm membrane filter 
• Syringes 
• Dissolution apparatus 
• pH meter 
7.3.4.4. Chemicals and Reagents: 
• Sorafenib working standard 
• Potassium dihydrogen phosphate  
• Orthophosphoric acid- HPLC grade 
• Methonol- HPLC grade 
• Tetrahydrofuran 
• Acetonitrile- HPLC grade 
• Purified water- Milli-Q-grade 
7.3.4.5. Dissolution conditions:  
• Medium 0.1 M HCl with 1% SLS. 
• Volume: 900ml 
• Temperature : 370C ± 0.50C 
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• Apparatus: USP type –II (paddle) 
• RPM: 75 rpm 
• Time interval : 5, 10, 15, 20, &30 min 
7.3.4.6. Preparation of Dissolution medium (0.1M HCl solution): 
 8.5ml of hydrochloric acid was pipetted  and dissolved in 1000ml of distilled water 
7.3.4.7. Chromatographic conditions: 
• Column- X-Terra RP- 18 (100 x 4.6mm), 5µm 
• Flow rate – 2.0ml/ minute 
• Detector Wavelength- UV-293nm 
• Column temperature- Ambient 
• Injection volume- 10µl 
• Run time- 15 minutes 
7.3.4.8. Preparations: 
Mobile phase preparation:  
               A  mixture of phosphate buffer, Acetonitrile and Tetrahydrofuran was 
prepared  in the  ratio of 530:395:75 V/V respectively. Filtered through 0.22µm 
membrane filter and degassed. 
Standard preparation:  
                 Accurately weighed and transferred about 20 mg of Sorafenib tosylate 
working standard into 100ml of volumetric flask and added about 60ml of dissolution 
medium and sonicated to dissolve. Cooled the solution to room temperature and 
diluted to volume with dissolution medium.Transferred 5.0ml of the standard stock 
preparation into a 100ml volumetric flask and diluted to volume with dissolution 
medium.  
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Sample preparation: 
                  One tablet equivalent to 200mg in each of six dissolution flasks containing 
1000ml of dissolution medium, previously maintained at 37ºC, taking care to exclude 
air bubbles from the surface of each dosage unit and immediately operated the 
apparatus for specified time intervals. After completion of each specified time 
interval, withdraw a portion of solution from zone midway between the surface of the 
dissolution medium and top of the rotating blade, not less than 1cm from vessel wall 
and filtered through 0.22μm membrane filter. Transferred 5.0ml of the above solution 
into a 100ml volumetric flask and diluted to volume with dissolution medium. 
7.3.4.9. System suitability: 
                  Chromatograph the standard preparation (Six replicate injections), measure 
the peak area responses for the analyte peak and evaluate the system suitability 
parameters as directed. 
7.3.4.10. Acceptance criteria: 
%RSD for replicate injections of peak area response of Sorafenib peak from 
the standard preparation should not be more than 2.0. 
The Tailing factor for Sorafenib peak should be not more than 2.0. 
The number of Theoretical plates for Sorafenib peak should be not less than 2000. 
7.3.4.11. Procedure: 
                 Separately injected equal volumes (about 10µl) of the dissolution medium 
as blank,12.5µg/ml standard preparation and sample preparation into chromatograph, 
and recorded the chromatograms and measured the peak area responses for the analyte 
peak. Calculated the % of drug dissolved of Sorafenib in the portion of Sorafenib 
tablets by the formula. 
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7.3.4.12. Calculation: 
% of Labeled amount of Sorafenib tosylte dissolved: 
𝑇𝐴
𝑆𝐴
𝑋
𝑆𝑊
200
𝑋
5
20
𝑋
900
1
𝑋
𝑃
100
𝑋
100
200
 
Where, 
TA- Peak area response due to sorafenib from sample preparation 
SA- Peak area response due to sorafenib from standard preparation 
SW- Weight of sorafenib working standard taken in mg 
P- Purity of sorafenib working standard, taken on as is basis 
. 
7.3.5. ASSAY: (By HPLC method) 
7.3.5.1. Instrument(LC 10): 
High performance liquid chromatograph equipped with UV-Detector and data 
handling system 
7.3.5.2. Apparatus: 
• Analytical balance 
• Volumetric flasks 
• Pipettes 
• 0.45µm membrane filter 
• Filtration unit 
• pH meter 
7.3.5.3. Chemicals and Reagents: 
• Sorafenib working standard 
• Potassium dihydrogen phosphate  
• Orthophosphoric acid- HPLC grade 
• Methonol- HPLC grade 
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• Tetrahydrofuran 
• Acetonitrile- HPLC grade 
• Purified water- Milli-Q-grade 
7.3.5.4. Chromatographic conditions: 
• Column- X-Terra RP- 18 (100 x 4.6mm), 5µm 
• Flow rate – 2.0ml/ minute 
• Wavelength- UV-265 nm 
• Column temperature- Ambient 
• Injection volume- 20µl 
• Run time- 15 minutes 
7.3.5.5. Preparations: 
Phosphate buffer preparation: 
                  2.72g of potassium dihydrogen orthophosphate was weighed and 
transferred  in to 1000ml of purified water and mixed. Adjusted the solution pH to 3.0 
with orthophosphoric acid. 
Mobile phase preparation: 
                A mixture of  phosphate buffer, Acetonitrile and Tetrahydrofuran were 
prepared  in the ratio of 530:395:75 v/v respectively. Filtered through 0.22µm 
membrane filter and degassed. 
Diluent preparation: 
   A mixture of Methanol and Acetonitrile  was prepared in the ratio of 50:50 v/v 
respectively. Filtered and degassed. 
Standard preparation: 
               50 mg equivalent  of Sorafenib tosylate working standard was weighed and 
taken  into 100ml of volumetric flask add about 60ml of dissolution medium and 
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sonicated to dissolved. Cool the solution to room temperature and dilute to volume 
with dissolution medium.Transferred 5.0ml of the standard stock preparation into a 
100ml volumetric flask and dilute to volume with dissolution medium. 
Sample preparation: 
               Weighed and finely powdered not fewer than 20 tablets.Transferred an 
accurately weighed portion of the  powder, equivalent to 200mg of Sorafenib into a 
250 ml volumetric flask. Added about 160ml of dissolution medium .Shaken for 15 
minutes on orbital shaker and sonicated for 30 minutes with occasional shaking.cool 
the solution to room temperature and diluted to volume with dissolution medium. 
Filtered the solution through 0.22µm membrane filter.Transferred 1.5 ml of the above 
filtered solution in to a 50ml  volumetric flask,   diluted to volume with diluent. 
7.3.5.6. System suitability: 
                 Chromatograph the standard preparation (Six replicate injections), measure 
the peak area responses for the analyte peak and evaluate the system suitability 
parameters as directed. 
7.3.5.7. Acceptance criteria: 
%RSD for replicate injections of peak area response of the Sorafenib peak 
from the standard preparation should be not more than 2.0 
The Tailing factor for Sorafenib peak should be not more than 2.0 
The number of Theoretical plates for Sorafenib peak should be not less than 2000. 
7.3.5.8. Procedure: 
                 Separately injected the equal volumes (about 20µl) of the diluent as blank, 
standard preparation and sample preparation into the chromatograph, and recorded the 
chromatograms and measured the peak area responses for the analyte peak. Calculate 
the % content of Sorafenib in the portion of Sorafenib tablets taken by the formula. 
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7.3.5.9. Calculation: 
% Content of sorafenib:  
𝑇𝐴
𝑆𝐴
𝑋
𝑆𝑊
𝑆𝑡𝑑. 𝑤𝑡
𝑋
100
25
𝑋
100
5
𝑋
250
𝑇𝑊
𝑋
200
3
𝑋
𝑃
100
𝑋𝐴𝑣𝑔. 𝑤𝑡 
Where, 
TA- Peak area response due to Sorafenib from Sample preparation 
SA- Peak area response due to Sorafenib from Standard preparation 
SW-  Sample weight of Sorafenib mg. 
TW- Weight of sample taken in mg 
P- Purity of Sorafenib working standard, taken on as is basis. 
Avg Wt- Average weight of tablet. 
Std.wt-Standard weight. 
7.3.6. STABILITY STUDY     (Manavalan R. and Ramasamy S., 2004; Suresh V.K., 
et   al.,2010) 
7.3.6.1. Introduction 
                 In any rational drug design or evaluation of dosage forms for drugs, the 
stability of the active component must be a major criterion in determining their 
acceptance or rejection. Stability of a drug can be defined as the time from the date of 
manufacture and the packaging of the formulation, until its chemical or biological 
activity is not less than a predetermined level of labelled potency and its physical 
characteristics have not changed appreciably or deleteriously. 
7.3.6.2. Objective of the study 
                  The purpose of stability testing is to provide evidence on how the quality 
of a drug substance or drug product varies with time under the influence of a variety 
of environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
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observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted. The International Conference on Harmonization (ICH) 
Guidelines titled “Stability testing of New Drug Substances and Products (QIA) 
describes the stability test requirements for drug registration application in the 
European Union, Japan and the States of America. 
ICH specifies the length of study and storage conditions  
7.3.6.3. Study specifications: 
Table 7.8: ICH Specifications to study the storage conditions 
S.NO. STUDY STORAGE CONDITION 
MINIMUM TIME 
PERIOD 
1. Long term 
25ºC+ 2ºC/60 %RH+ 5ºC (or) 
30C+2ºC/ 65%RH+5%RH 
12 months 
2. Intermediate 30ºC+2ºC/65%RH+5%RH 6months 
3. Accelerated 40ºC +2ºC / 75% RH +5 % RH 6months 
 
  
 
 
 
 
 
 
 
RESULTS 
AND  
DISCUSSION 
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8. RESULTS AND DISCUSSION 
8.1. PREFORMULATION PARAMETERS 
 8.1.1. Identification of drug 
8.1.1.1. Identification by HPLC Chromatographic method: 
 
Figure 8.1: The HPLC Chromatogram of assay of Sorafenib Tosylate (Standard) 
 
 
 
Figure 8.2: The HPLC Chromatogram of assay of Sorafenib Tosylate (Sample)  
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8.1.1.2. Melting point: 
Melting point of Sorafenib Tosylate sample was found to be 230
0
C.Hence, 
experimental value are in good agreement with official values. 
8.1.2. Physicochemical parameters of drug: 
8.1.2.1. Organoleptic properties: 
Odour     :  Charecteristic odour 
Colour    :  A White to yellowish powder 
Nature   : Crystalline powder 
8.1.2.2. Solubility study: 
Table 8.1: Solubility of Sorafenib in different solvents 
                          
                            Table .8.2:  FLOW PROPERTIES OF API  
S.No  Flow Properties  Result  
1.  Bulk density (g/ml)  0.206  
2.  Tapped density (g/ml)  0.360  
3.  Carr‟s index (%)  9 
4.  Hausner‟s ratio  1.7  
5.  Angle of repose(˚)  24°.4  
 
Name of solvents Solubility 
Poly ethylene glycol   Soluble 
Methanol  Soluble 
0.1N HCl Soluble 
Distilled water Practically insoluble 
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8.1.3. Analytical methods 
8.1.3.1. Preparation of standard graph of Sorafenib tosylate: 
 The drug obeys Beer- Lambert‟s law in the range of 10–50μg /ml. 
          Table 8.3:  Data of concentration and Area of the peak for Sorafenib tosylate in 
0.1N HCl 
S. No. Concentration 
(µg/ml) 
Area of the peak 
1 10 127750 
2 20 255500 
3 30 383250 
4 40 511000 
5 50 638750 
 
 
Figure 8.3: Standard graph of Sorafenib tosylate 
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Table 8.4: Calibration parameter values in 0.1 N HCl 
S. No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope (m)  12774.99 
3 Intercept (c) 0.75 
 
 
 
                  
                 Figure 8.4: Determination of compatibility for drug with polymer 
By HPLC Chromatographic method 
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                    Table 8.6: The HPLC chromatogram of Sorafenib(intial) 
Impurities present in Sorafenib tosylate 
S.no Peak name RT Area %Area 
1 Unknown-1 6.572 507 0.00 
2 Unknown-2 7.867 3375 0.01 
3 Impurity-C 16.576 8315 0.02 
4 Sorafenib 17.251 37000085 99.97 
 
Impurity A: 4-(2-(N-methyl carbonyl)-4-pyrydyloxy) aniline.  
Impurity B: 1, 3-Bis (4-chloro-3-di floro phenyl) phenyl urea  
Impurity C: 4 (- 4 ((((2-chloro-3-tri floro methyl) phenyl) amino) carbonyl) 
amino)- phenyl)-N-methyl-2-pyridine carboxamide tosylate.           
 
                     
       Figure 8.5: The HPLC Chromatogram of Sorafenib Impurities (2 weeks) 
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              Table 8.7:  Impurities that are present in Sorafenib(2 weeks) 
   
 
 
 
 
 
                                      Table 8.8: compatibility study specifications 
RERLATIVE SUBSTANCE SPECIFICATIONS (%) 
     Impurity A NMT 0.15 
     Impurity B NMT 0.15 
     Impurity C NMT 0.15 
     Highest unknown impurity NMT 0.10 
     Total impurity NMT 0.5 
 
 
               Table 8.9: Sorafenib tosylate compatibility studies (Initial) 
 
RERLATIVE 
SUBSTANCE 
 
      Impurity A 
 
 
     Impurity B 
 
 
    Impurity C 
 
      Single max 
     unknown                                                
      impurity 
Total         
Impurity
Sorafenib tosylate 0.016 ND 0.056 0.013 0.079 
Sorafenib+ 
microcrystalline 
Cellulose 
0.014 ND 0.043 0.09 0.071 
 Sorafenib + 
croscarmellose 
 Sodium 
0.014 ND 0.045 0.013 0.072 
Sorafenib+ sodium 
lauryl  
Sulphate 
0.017 ND 0.042 0.013 0.072 
Sorafenib+HPMC E5 0.014 ND 0.045 0.011 0.070 
Sorafenib+ magnesium  
State 
0.015 ND 0.055 0.012 0.084 
Sorafenib+ advantia 
prime 
 Pink 
0.018 ND 0.052 0.012 0.082 
Sorafenib+ povidone 0.32 ND 0.40 0.013 0.73 
Sorafenib+cross 
povidone 
0.28 ND 0.20 0.20 0.68 
 
 
S .no Peak name RT Area %Area 
1 Unknown-1 6.411 511 0.00 
2 Unknown-2 7.672 3867 0.01 
3 Unknown-3 14.810 492 0.00 
4 Unknown-4 15.043 416 0.00 
5 Impurity-C 16.221 8290 0.02 
6 Sorafenib 16.850 35791516 99.96 
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      Table 8.10: Sorafenib tosylate compatibility studies (2 weeks) at 55
0
C 
 
RERLATIVE 
SUBSTANCE 
 
      Impurity A 
 
 
    Impurity B 
 
 
    Impurity C 
 
Single max  
unknown 
impurity 
  
Total 
Impurity 
Sorafenib tosylate 0.016 ND 0.056 0.012 0.084 
 Sorafenib+ 
microcrystalline cellulose 
0.017 ND 0.043 0.011 0.009 
  Sorafenib+croscarmellose 
 Sodium 
0.015 ND 0.045 0.011 0.074 
   Sorafenib+ sodium lauryl  
Sulphate 
0.019 ND 0.049 0.011 0.083 
Sorafenib+HPMC E5 0.021 ND 0.049 0.012 0.086 
           Sorafenib+ magnesium 
                    State 
0.020 ND 0.053 0.012 0.081 
Sorafenib+ advantia prime  
Pink 
0.015 ND 0.052 0.013 0.012 
Sorafenib+ povidone 0.35 ND 0.43 0.012 0.12 
Sorafenib+cross povidone 0.82 ND 0.20 0.14 0.75 
 
 
 
     Table 8.11: Sorafenib tosylate compatibility studies (28days) at 40
0
C+2
0
C/75+5%RH 
 
RERLATIVE 
SUBSTANCE 
 
      Impurity A 
 
 
    Impurity B 
 
 
     Impurity C 
 
Single max                                                                                
unknown  
        impurity 
 
Total  
Impurity 
Sorafenib tosylate 0.028 ND 0.056 0.012 0.091 
Sorafenib+ 
microcrystalline  
Cellulose 
0.015 ND 0.041 0.009 0.065 
  Sorafenib+croscarmellose  
Sodium 
0.016 ND 0.043 0.010 0.069 
 Sorafenib+ sodium lauryl  
Sulphate 
0.019 ND 0.067 0.011 0.097 
Sorafenib+HPMC E5 0.020 ND 0.051 0.012 0.083 
Sorafenib+ magnesium  
State 
0.020 ND 0.052 0.012 0.083 
Sorafenib+ advantia prime  
Pink 
0.019 ND 0.050 0.012 0.081 
Sorafenib+ povidone 0.39 ND 0.40 0.012 0.73 
Sorafenib+cross povidone 0.64 ND 0.20 0.016 0.74 
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Impurity A: 4-(2-(N-methyl carbonyl)-4-pyrydyloxy) aniline. 
Impurity B: 1, 3-Bis (4-chloro-3-di floro phenyl) phenyl urea 
Impurity C: 4 (- 4 ((((2-chloro-3-tri floro methyl) phenyl) amino) carbonyl) amino)- 
phenyl)-N-methyl-2-pyridine carboxamide tosylate. 
 
The increase in impurities at the initial stage is found in Povidone and Cross 
Povidone. So these are incompatible with active ingredient. Hence, it is recommended 
that the above excipients (Povidone, Cross Povidone) cannot be used in further 
formulation development trials. 
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8.1.4. Differential scanning calorimetry: 
The compatibility and interactions between drug and excipients like  SLS and 
CCS were studied using differential scanning calorimetry and the results were  shown 
in figure  8.6,8.7,8.8.                
 
                 Figure:8.6.DSC Thermal analysis of Sorafenib tosylate 
                
             Figure:8.7.DSC Thermal analysis of Sorafenib tosylate + SLS 
               
                Figure :8.8. DSC  Thermal analysis of Sorafenib Tosylate + CCS 
From the above thermogram, it can selected that there is no change in the 
peak. Hence, no interaction between drug and excipients. 
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 8.2. Evaluation of powder blends: 
The blended powders of different formulations were evaluated for angle of repose, 
loose bulk density, tapped bulk density, compressibility index and Hausner ratio. The 
results of these evaluations were as follows: - 
                        Table 8.12: Flow characteristics of powder blends 
Formulation 
Code 
Angle of 
repose (
o
) 
Loose bulk 
density 
(g/ml) 
Tapped 
bulk 
density 
(g/ml) 
Hausner 
ratio 
Carr‟s index 
(%) 
F1 32.0±0.173 0.158±0.00 0.731±0.00 1.44±0.00 29.05±0.049 
F2 27.51±0.05 0.434±0.00 0.500±0.00 1.14±0.00 12.3±0.11 
F3 26.34±0.005 0.427±0.00 0.495±0.00 1.14±0.00 13.6±0.05 
F4 25.45±0.005 0.445±0.00 0.505±0.00 1.13±0.00 11.8±0.05 
F5 26.65±0.005 0.400±0.00 0.471±0.00 1.17±0.00 14.8±0.05 
F6 27.04±0.005 0.416±0.00 0.482±0.00 1.15±0.00 13.4±0.05 
F7 26.45±0.005 0.394±0.00 0.461±0.00 1.17±0.00 14.4±0.05 
F8 26.28±0.005 0.427±0.00 0.490±0.00 1.14±0.00 12.6±0.05 
F9 27.15±0.005 0.416±0.00 0.485±0.00 1.16±0.00 14.1±0.05 
*All the values were expressed as mean± SD, n=3 
 
8.2.1. Angle of repose: 
            Angle of repose ranged from25.45±0.005 to 32.0±0.1. The results were found 
to be 25º to 35º and hence the blend was found to have excellent flowability. 
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 8.2.2. Loose bulk density and tapped bulk density:   Bulk and tapped densities are 
used for the measurement of Compressibility index. The LBD and TBD ranged from 
0.158 ± 0.00 to 0.445± 0.00 g/ml; and 0.461 ± 0.00 to 0.731± 0.00 g/ml respectively 
 
8.2.3. Compressibility index (Carr’s index): 
The compressibility index  ranged from 11.8± 0.11to 29.05± 0.049 .The blend 
was found to have good flowing property as the result were found to be below 20 
 
 8.2.4. Hausner ratio: 
The Hausner ratio ranged from 0.13± 0.00 to 1.17 ± 0.00. The result indicates 
the free flowing properties of the powders. 
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8.3. Evaluation of Immediate release tablets 
8.3.1. Appearance: 
Surface nature of tablets was observed visually and it was concluded they did 
not show any defects such as capping, chipping and lamination.  
8.3.2. Physico-chemical characteristics:  
The physical characteristics of Sorafenib tosylate tablets (F1 toF9) such as thickness,  
hardness, friability, weight variation and drug content were determined. 
                 Table 8.13: Physico-chemical parameters of Sorafenib tosylate tablets  
F. 
Code 
Thickness 
(mm) 
Hardness 
(kg/cm
2
) 
Friability 
(%) 
Weight 
variation 
(mg) 
Drugcontent 
(%w/w) 
F1 5.50±0.00 6.9±0.05 0.12 400.40±1.50 95±0.115 
F2 4.63±0.01 7.3±0.05 0.06 402.15±2.94 97.3±0.05 
F3 4.87±0.00   7.3±0.05 0.17 400.90±2.73 94.2±0.115 
F4 4.90±0.00 7.4±0.05 0.17 401.25±3.57 97.8±0,05 
F5 5.43±0.00 7.5±0.01 0.15 402.20±3.61 99.9±0.05 
F6 5.82±0.00 7.8±0.05 0.18 401.75±2.22 97.4±0.05 
F7 5.07±0.00 7.8±0.05 0.09 400.80±3.24 98.3±0.05 
F8 4.67±0.00 7.9±0.05 0.16 403.05±3.12 92.4±0.05 
F9 5.42±0.00 7.5±0.05 0.16 402.95±2.28 97.6±0.05 
                        All the values were expressed as mean ± SD, n=3 
8.3.2.1. Thickness  
 The  thickness ranged between 4.63 ± 0.00 to 4.87 ± 0.00 mm. 
8.3.2.2. Tablet hardness:  
 The hardness of tablets was found to be in the range from 6.9± 0.65 kg/cm
2 
to 
7.9 ± 0.05kg/cm
2
. This indicates good mechanical strength of tablet. 
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8.3.2.3. Percent friability: 
Percentage friability of all the formulations was found to be in the range from 
0.06 to 0.18 %. This indicates good handling property of the tablet. 
8.3.2.4. Weight variation: 
A tablet is designed to contain a specific amount of drug. When the average 
weight of the tablet is 400 mg, the pharmacopoeial limit for percentage deviation is ± 
5%. The percentage deviation from average tablet weight for all the tablet was found 
to be within the specified limits and hence all formulations complied with the test for 
weight variation according to the pharmacopoeial specifications IP 2007. 
8.3.3. Drug content: 
 The drug content of all the formulation was found to be in the range from 92.4 
± 0.05 to 99.9 ± 0.05 % w/w, which was within the specified limit as per IP 2007. 
8.3.4. In-vitro disintegration studies: 
Table 8.14: Disintegration time of formulations (F1toF9) 
Code Disintegration 
time(min) 
F1 29±0.57 
F2 9.0±0.05 
F3 8.5±0.05 
F4 5.8±0.05 
F5 5.5±0.05 
F6 5.1±0.05 
F7 8.29±0.05 
F8 20±0.05 
F9 5.7±0.05 
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8.3.5. In-vitro Dissolution Studies: 
Table 8.15:  Dissolution data of formulation F1 
S.No Dissolution  
Medium 
Time (min) Drug released* 
(%) 
1  
 
0.1N HCl 
0 0.00 
2 5 42.1±0.057 
3 10 62.1±0.115 
4 15 73.2±0.208 
5 20 79.2±0.15 
6 30 81.1±0.057 
*All values are expressed as mean ±S.D. n=3.
 
        
                                        Figure 8.9: Invitro drug release of formulation F1 
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Table 8.16:  dissolution data of formulation F2 
S.No Dissolution 
medium 
Time (min) Drug 
released* 
(%) 
       1  
 
  0.1N HCl 
0 0.00 
2 5 44.2±0.057 
3 10   56.1±0.208 
4 15 69.0±0.152 
5 20 74.2±0.208 
6 30 85.2±0.1 
*All values are expressed as mean ±S.D. n=3. 
 
 
 
Figure 8.10:  InVitro drug release profile of formulation F2 
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Table 8.17:  Dissolution data of formulation F3 
S.No Dissolution 
medium  
Time (min) Drug 
released* 
(%) 
1  
 
0.1N HCl 
0 0.00 
2 5 50.6±0.55 
3 10 55.2±0.057 
4 15 70.5±0.585 
5 20 75.1±0.781 
6 30    85.2±0.057 
*All values are expressed as mean ±S.D., n=3. 
 
 
  
Figure 8.11:  InVitro drug release profile of formulation F3 
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Table 8.18: Dissolution data of formulation F4 
S.No Dissolution  
medium 
Time (min) Drug released  
(%) 
1  
 
0.1N HCl 
0 0.00 
2 5 42.1±0.057 
3 10 54.0±0.208 
4 15 62.1±0.115 
5 20 74.2±0.208 
6 30 82.1±0.057 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
Figure 8.12:  InVitro drug release profile of formulation F4 
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Table 8.19:  Dissolution data of formulation F5 
S.No Dissolution 
medium 
Time (min) Drug 
released* 
(%) 
1  
 
0.1NHCl 
0 0.00 
2 5 55.3±0.208 
3 10 72.6±0.351 
4 15 83.5±0.10 
5 20 94.6±0.450 
6 30 100.1±0.1 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
Figure 8.13:  InVitro drug release profile of formulation F5 
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Table 8.20:  Dissolution data of formulation F6 
S.No Dissolution 
medium 
Time (min) Drug 
released* 
(%) 
1  
 
0.1NHCl 
0 0.00 
2 5 49.1±0.152 
3 10 62.2±0.152 
4 15 76.1±0.208 
5          20 84.2±0.057 
6         30  96.9±0.493 
*All values are expressed as mean ±S.D., n=3 
. 
 
 
Figure 8.14:  InVitro drug release profile of formulation F6 
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                              Table.8.21: Dissolution data of formulation F7 
S.No Dissolution 
medium 
Time (min) Drug 
released* 
(%) 
1  
 
0.1NHCl 
0 0.00 
2 5 56.2±0.208 
3 10 69.1±0.152 
4 15 73.1±0.208 
5 20 82.1±0.057 
6 30 97.1±0.115 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
Figure 8.15: InVitro drug release profile of formulation F7 
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                        Table 8.22:  Dissolution data of formulation F8 
S.No Dissolution 
medium 
Time (min) Drug 
released* 
(%) 
1  
 
0.1NHCl 
0 0.00 
2 5 51.2±0.057 
3 10 62.2±0.152 
4 15 70.5±0.152 
5 20 75.2±0.057 
6 30 78.3±0.152 
*All values are expressed as mean ±S.D., n=3. 
 
 
Figure 8.16:  InVitro drug release profile of formulation F8 
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Table 8.23: Dissolution data of formulation F9 
S.No Dissolution 
medium 
Time (min) Drug 
released* 
(%) 
1  
 
0.1NHCl 
0 0.00 
2 5 62.1±0.115 
3 10 78.1±0.115 
4 15 86.1±0.1 
5 20 90.1±0.057 
6 30 98.1±0.1 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
Figure 8.17:  InVitro drug release profile of formulation F9 
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Table 8.24: Dissolution data of Innovater 
S.No Dissolution 
medium 
Time (min) Drug 
released* 
(%) 
1  
 
0.1NHCl 
0 0.00 
2 5 58.2±0.20 
3 10 72.2±0.35 
4 15 86.1±0.10 
5 20 97.2±0.11 
6 30 100.3±0.10 
*All values are expressed as mean ±S.D., n=3. 
 
 
 
 
Figure 8.18:  InVitro dissolution of innovator 
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Figure 8.19: Comparision of invitro drug release (F1-F9) 
Table 8.25:  Time of drug release values of t25 , t50 and t90 for formulations (F1 to F9). 
 
Formulation 
code 
Time of %Drug release(min) 
t25% t50% t90% 
F1 2.96 8.05 - 
F2 2.82 8.91 - 
F3 2.47 9.05 - 
F4 2.96 9.25 - 
F5 2.26 4.52 19.02 
F6 2.25 8.01 27.86 
F7 2.21 7.22 27.77 
F8 2.44 8.05 - 
F9 2.01 8.05 27.52 
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Figure 8.20:Time of drug release values of t25,t50 and t90 for formulations (F1 to F9). 
8.4. STABILITY STUDY 
   After exposure to accelerated stability conditions the formulation was 
analyzed for various evaluation parameters. 
Table 8.26:Stability studies of optimized formulation (F5).  
Parameter Initials 1 Month 2 Month 3 Month 
Description 
 
Pink coloured 
round shaped film 
coated tablet 
complies complies Complies 
Assay(%w/w) 99.9±0.05 99.6±0.01 98.6±1.02 98.1±0.98 
Dissolution(%w/v) 100.1±0.95 99±0.75 97.5±1.23 96.2±1.72 
Hardness(kg/cm²) 7.5±0.01 7.2±1.0 6.6±0.5 6.1±1.0 
Disintegration 
time(min) 
5.5±0.05 5.32±0.30 5.25±0.26 5.20±0.8 
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Figure 8.21:Comparision of %drug content of before and after stability studies 
of formulation f5 
 
 
 
Figure 8.21:Comparision of in-vitro drug release profile of before and after stability 
studies of formulation f5 
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Figure 8.22:Comparision of hardness of the tablet before and after   stability 
studies of  formulation f5 
 
 
Figure 8.23:Comparision of disitntigration time of the tablet after and before stability 
studies of formulation f5 
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From the above studies there was no significant difference was initiate 
between the evaluated data from initial and after stability studies  and all the values 
were found in worth accepting limit .The  best formulation was showed adequate 
physical stability at 40 º±2ºC at 75%±5% relative humidity. 
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9. SUMMARY AND CONCLUSION 
             A Succesful immediate drug delivery system was prepared with immediate 
release mechanism that gives immediate on set of  action, and compared with that of 
marketed product. 
 Sorafenib tosylate posses Longer half life and  hence it was a good candidate 
for Immediate release drug delivery system. The identification of drug was carried out 
by HPLC and melting point. The physicochemical parameters such as appearance, 
solubility study were performed by suitable methods. The analytical profile of drug 
was evaluated for development of standard curve and percentage purity of drug. 
Compatibility of drug and ingredients was done by performing HPLC and DSC study. 
It was concluded that there was no interaction between the drug and disintegrants as 
the   Impurities present in the drug were found unaltered in the HPLC chromatogram 
and peaks in the DSC thermogram of drug disintegrant physical mixture. The powder 
blend was prepared by blending the various ingredients in mortar and pestle for 20 
min and evaluated for bulk density, tapped density, carr‟s index, hausner‟s ratio and 
angle of repose.  
  Immediate release tablet of Sorafenib tosylate was obtained by wet 
granulation and dry granulation method for all the formulations F1 to F9. 
Formulations prepared composed of , croscarmellose sodium,and sodium starch 
glycolate as disintegrants with other excipients like micro crystalline cellulose as 
diluent, HPMC E-5 as a binder, microcrystalline cellulose pH 102 as a Filler, 
magnesium stearate as a lubricant. The all formulations were evaluated for the 
appearance, hardness, percent friability, weight variation, drug content, and In-Vitro 
drug released. On the performance with respect to disintegration time and the drug 
release characteristics, the formulation F5 was selected as the best formulation as it is 
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showed a 10% disintegration time and high release as compared to marketed product. 
This formulation showed a Immediate release rate. And the formulation shows 
100.1% release in 30 minutes. 
  In the present study the effect of superdisintegrants studied on In-Vitro 
disintegration time and In-Vitro drug release. It shows that immediate release  was 
achieved by absorbing the water in to the tablet By the action of superdisintegrants. 
             The study has revealed that by interchanging the disintegrant, release rate of 
drug was improved and results confirmed that the release rate from  tablets depends 
on type of disintigrant. 
 According to stability study it was found that there was no significant change 
in hardness, drug content and In-Vitro dissolution of optimized formulation F5. 
  It may be concluded that the immediate release tablets of Sorafenib tosylate 
was feasible and may be manufactured with reproducible characteristics with the aid 
of Croscarmellose sodium as super disintegrants. From the above all trials we 
conclude that formulation-5 obeys all the results within the Standard limits as that of 
innovator product.  However it needs further in depth animal studies on suitable 
animal models with statistical clinical data for a dependable and successful 
pharmaceutical marketing formulation. 
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10.  FUTURE PROSPECTS 
     In the present work, the immediate release tablets of Sorafenib tosylate 
were prepared by wet granulation technique using different  ratios disintegrants  and 
surfactants. 
 In this work, only physiochemical characterization such as angle of repose, 
Carr‟s index, hausner ratio, weight variation, hardness, thickness, friability, drug 
content and in vitro evaluation of Sorafenib tosylate of immediate release tablet was 
performed. Along with in vitro studies, in vivo studies of drug are most important. 
In future in vivo studies are required to set the in vitro - in vivo            
correlation (IVIVC) which is necessary for development of successful         
formulation and also long term stability studies are necessary. 
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